Data / Research funding / Antimicrobial Resistance
Antimicrobial Resistance: 2,124 NIH awards ($3.3B) to 503 organizations
2,124 NIH awards ($3.3B) in the NIH spending category Antimicrobial Resistance, to 503 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
The 500 largest of 2,124 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $472,070,715 | December 1, 2024 | November 30, 2025 | CURRIER, JUDITH S. | reporter.nih.gov |
| Antibacterial Resistance Leadership Group (ARLG) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $78,031,274 | June 1, 2013 | November 30, 2026 | FOWLER, VANCE G. | reporter.nih.gov |
| Microbiology and Infectious Diseases Biological Resource Repository (MID-BRR) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $63,039,784 | May 5, 2022 | October 31, 2023 | WILLIAMS, CARLA | reporter.nih.gov |
| DMID Clinical Research Operations & Management Support (CROMS): mpox activities | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $47,983,949 | April 1, 2024 | March 31, 2026 | ELLIS, JESSICA | reporter.nih.gov |
| Task D02: Pre-Clinical Pharmacokinetic Services | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $27,852,554 | February 25, 2019 | February 24, 2020 | MIRSALIS, JON | reporter.nih.gov |
| University of North Carolina Global HIV Prevention and Treatment Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $24,477,809 | February 1, 2007 | November 30, 2027 | ERON, JOSEPH J | reporter.nih.gov |
| Vaccine and Treatment Evaluation Units | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $22,981,366 | December 11, 2019 | November 30, 2026 | ROUPHAEL, NADINE GEORGES | reporter.nih.gov |
| Development of Therapeutic Products for Antibiotic Resistant Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $21,835,693 | July 1, 2020 | August 31, 2026 | PEVEAR, DANIEL | reporter.nih.gov |
| Development of Therapeutic Products for Antibiotic Resistant Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $21,157,224 | July 1, 2020 | January 31, 2025 | CIRZ, RYAN | reporter.nih.gov |
| Chemistry Center for Combatting Antibiotic-Resistant Bacteria (CC4CARB) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $19,637,160 | February 1, 2025 | January 31, 2026 | BLOUGH, BRUCE | reporter.nih.gov |
| Development of Therapeutic Products for Antibacterial Resistant Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $17,380,862 | September 9, 2019 | January 31, 2026 | OSCHNER, URS | reporter.nih.gov |
| Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $16,069,735 | September 22, 2022 | August 31, 2025 | CIRZ, RYAN | reporter.nih.gov |
| Development of Therapeutic Products for Antibiotic Resistant Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $14,810,179 | July 1, 2020 | October 19, 2025 | OCHSNER, URS ARNOLD | reporter.nih.gov |
| University of Rochester Vaccine and Treatment Evaluation Unit (VTEU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $14,263,529 | December 11, 2019 | November 30, 2026 | FALSEY, ANN R | reporter.nih.gov |
| Establishment of the New York University Vaccine and Treatment Evaluation Unit (NYU VTEU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $13,340,237 | April 10, 2020 | November 30, 2026 | MULLIGAN, MARK JOSEPH | reporter.nih.gov |
| Successful Clinical Response In Pneumonia Therapy (SCRIPT) Systems Biology Center | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,773,513 | January 17, 2018 | December 31, 2027 | WUNDERINK, RICHARD G | reporter.nih.gov |
| Advanced Development of Vaccine Candidates for Antibiotic Resistant Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,268,155 | September 1, 2020 | March 31, 2027 | MALINOWSKI, FRANK | reporter.nih.gov |
| Development of Therapeutic Products for Biodefense, Anti-Microbial Resistant (AMR) Infections and Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $10,977,909 | September 21, 2022 | November 8, 2024 | TOMARAS, ANDREW | reporter.nih.gov |
| Development of Therapeutic Products for Biodefense, AntiMicrobial Resistant (AMR) Infections and Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $10,501,521 | May 17, 2021 | December 31, 2026 | KANE, BRIAN | reporter.nih.gov |
| Development of Therapeutic Products for Biodefense and Emerging Antibiotic-Resistant Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $10,313,540 | September 23, 2016 | March 31, 2026 | HENKEL, TIMOTHY | reporter.nih.gov |
| GHESKIO Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $9,655,243 | February 1, 2007 | November 30, 2027 | PAPE, JEAN WILLIAM | reporter.nih.gov |
| Task B1: Phase I Clinical Trial to Evaluate a Therapeutic for Antibiotic Resistant Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $9,576,633 | May 13, 2021 | January 31, 2025 | BURMAN, BRIDGETT | reporter.nih.gov |
| FEND for TB | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $7,632,771 | June 4, 2020 | May 31, 2026 | ELLNER, JERROLD J. | reporter.nih.gov |
| 1/2: AZithromycin Therapy in Preschoolers with a Severe Wheezing Episode Diagnosed at the Emergency Department (AZ-SWED) | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $6,867,462 | September 15, 2020 | December 15, 2026 | MARTINEZ, FERNANDO D | reporter.nih.gov |
| Complementing broadly neutralizing antibodies and autologous responses to restrict virus escape and durably suppress HIV-1 | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $6,685,272 | April 11, 2022 | March 31, 2027 | BAR, KATHARINE JUNE | reporter.nih.gov |
| Advanced Development of Vaccine Candidates for Biodefense and Emerging Antibiotic-Resistant Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $6,612,767 | September 21, 2022 | January 18, 2026 | KRUISWIJK, CORINE | reporter.nih.gov |
| Advanced Development of Vaccine Candidates for Biodefense and Emerging Antibiotic-Resistant Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $6,592,393 | September 23, 2022 | July 22, 2026 | NORTON, ELIZABETH | reporter.nih.gov |
| Stellenbosch University Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,524,563 | April 15, 2007 | November 30, 2027 | HESSELING, ANNEKE CATHARINA | reporter.nih.gov |
| Dissecting the mechanisms of HIV resistance in vivo to broadly neutralizing antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $6,461,018 | August 9, 2022 | May 31, 2027 | HERSCHHORN, ALON | reporter.nih.gov |
| Task A82: Murine Models of UTI Caused by Antibiotic-Resistant Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,424,343 | July 19, 2023 | February 27, 2025 | GALLACHER, ANTHONY | reporter.nih.gov |
| Combatting AntiMicrobial Resistance in Africa Using Data Science (CAMRA) | NIH | Fogarty International Center | 2021 to 2025 | $6,419,538 | September 15, 2021 | June 30, 2027 | HAPPI, CHRISTIAN T. | reporter.nih.gov |
| Development of Therapeutic Products for Antibiotic Resistant Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $6,358,495 | July 1, 2020 | July 28, 2026 | BOWLIN, TERRY | reporter.nih.gov |
| Novel cyclic boronate Penicillin Binding Protein Inhibitors to eliminate the threat posed by β-lactamases and enable a future treatment option for carbapenem-resistant Enterobacterales infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,328,779 | May 4, 2021 | April 30, 2027 | BOYD, STEVEN ARMEN | reporter.nih.gov |
| Defining the mechanisms of HIV resistance to bNAbs in humans | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $6,279,096 | July 5, 2022 | April 30, 2027 | CASKEY, MARINA | reporter.nih.gov |
| INSPIRE (INtelligent Stewardship Prompts to Improve Real-time Empiric Antibiotic Selection for Patients): The INSPIRE-ASP Trial for Intra-Abdominal and Skin and Soft Tissue Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $6,161,229 | June 19, 2020 | May 31, 2026 | PLATT, RICHARD | reporter.nih.gov |
| Developing Teixobactin for Respiratory Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,154,703 | March 22, 2021 | February 28, 2027 | HUGHES, DALLAS | reporter.nih.gov |
| Structural Genomics Centers for Infectious Diseases: SARS-CoV-2 Research Activities | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $5,706,284 | September 1, 2017 | August 31, 2022 | SATCHELL, KARLA | reporter.nih.gov |
| Critical Factors Influencing Echinocandin Resistance in Candida glabrata | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,673,964 | August 1, 2014 | July 31, 2028 | PERLIN, DAVID S | reporter.nih.gov |
| DRAMATIC Phase 2 Duration Randomized MDR-TB Treatment Trial | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,484,466 | August 21, 2020 | May 31, 2026 | NAHID, PAYAM | reporter.nih.gov |
| Evaluation of doxycycline post-exposure prophylaxis to reduce sexually transmitted infections in PrEP users and HIV-infected men who have sex with men | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $5,430,840 | April 12, 2019 | March 31, 2025 | LUETKEMEYER, ANNE FREY | reporter.nih.gov |
| DEVELOPMENT OF IN VITRO DIAGNOSTICS FOR ANTIMICROBIAL RESISTANCE ESCHERICHIA COLI | NIH | National Institute of Allergy and Infectious Diseases | 2023 | $5,422,657 | July 24, 2023 | July 31, 2026 | SAMPATH, RANGARAJAN | reporter.nih.gov |
| Task V31: Process Development for a Panfungal Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,346,445 | January 20, 2023 | July 30, 2025 | FOUTS, TIM | reporter.nih.gov |
| Sialic acid analogs against multidrug-resistant gonorrhea | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,099,184 | April 20, 2021 | March 31, 2027 | RAM, SANJAY | reporter.nih.gov |
| tRNA in codon usage | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $5,063,701 | March 1, 2020 | August 31, 2029 | HOU, YA-MING | reporter.nih.gov |
| Task 12: Sexually Transmitted Infections Clinical Trials Group: Phase 2 Clinical Trial to Evaluate a Vaccine Candidate for Neisseria Gonorrhoeae | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,969,800 | September 6, 2019 | June 30, 2026 | HOOK, EDWARD | reporter.nih.gov |
| Bacteriophage-based approach for managing Shigella infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,946,719 | May 5, 2020 | April 30, 2026 | SULAKVELIDZE, ALEXANDER | reporter.nih.gov |
| Autonomously deploying, co-evolving SARS-CoV-2 antiviral: a new paradigm for pandemic prevention | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $4,817,583 | September 24, 2021 | August 31, 2024 | RODICK, ROBERT | reporter.nih.gov |
| Optimal chemopreventive regimens to prevent malaria and improve birth outcomes in Uganda | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,809,096 | April 15, 2020 | March 31, 2026 | DORSEY, MATTHEW G | reporter.nih.gov |
| Novel Stem Cell Immunotherapy for MDR-Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,800,190 | June 4, 2021 | May 31, 2026 | JAGANNATH, CHINNASWAMY | reporter.nih.gov |
| Algorithms and Software for the Assembly of Metagenomic Data | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,774,331 | March 21, 2013 | August 31, 2029 | POP, MIHAI | reporter.nih.gov |
| PRESCIENT: A phase IIc, open-label, randomized controlled trial of ultra-short course bedaquiline, clofazimine, pyrazinamide and delamanid versus standard therapy for drug-susceptible tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,716,636 | May 1, 2025 | April 30, 2027 | KOENIG, SERENA PATRICIA | reporter.nih.gov |
| Advanced Development of Vaccine Candidates for Biodefense and Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,706,565 | September 21, 2022 | April 30, 2027 | THAMMAVONGSA, VILASACK | reporter.nih.gov |
| Clinical Trial Site Monitoring for PHOENIx MDR-TB | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,653,435 | April 15, 2025 | December 14, 2025 | SMITH, KIMBERLY | reporter.nih.gov |
| New class of PBP inhibitors to address PBP2-mediated resistance in Neisseria gonorrhoeae | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $4,603,680 | September 5, 2019 | August 31, 2025 | DAIGLE, DENIS MARC | reporter.nih.gov |
| Discovering antimicrobials acting against MDR pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,469,088 | September 2, 2022 | August 31, 2026 | LEWIS, KIM | reporter.nih.gov |
| Structure, function, and regulation of the bacterial transcription cycle | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $4,361,466 | May 1, 2016 | April 30, 2027 | DARST, SETH A. | reporter.nih.gov |
| Task C24: Process Optimization and Scale Up of an Antibiotic-Resistant Bacterial Agent | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,247,326 | July 19, 2024 | January 18, 2026 | SCHLAGER, HEIDI | reporter.nih.gov |
| Development of In Vitro Diagnostics for Biodefense, Antimicrobial Resistant Infections(AMR), and Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $4,211,973 | September 18, 2024 | September 17, 2029 | LENIGK, RALF | reporter.nih.gov |
| TrmD-targeting actinobacterial natural products as next generation antibiotics | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,187,325 | June 25, 2021 | May 31, 2027 | HOU, YA-MING | reporter.nih.gov |
| Programmable benchtop bioreactors for scalable eco-evolutionary dynamics of the human microbiome | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,135,886 | June 10, 2022 | May 31, 2027 | KHALIL, AHMAD SAMIR | reporter.nih.gov |
| Bacillus subtilis stress responses | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $4,031,818 | June 1, 2017 | May 31, 2027 | HELMANN, JOHN D | reporter.nih.gov |
| Structure-based microbially targeted prodrugs | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,024,546 | September 1, 2022 | August 31, 2027 | ODOM JOHN, AUDREY RAGAN | reporter.nih.gov |
| A single antiviral to treat multiple opportunistic infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,962,651 | June 15, 2014 | March 31, 2026 | REMISZEWSKI, STACY | reporter.nih.gov |
| Efficacy of immunization with 4C-MenB in preventing experimental urethral infection with Neisseria gonorrhoeae. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,925,773 | July 1, 2021 | April 30, 2027 | DUNCAN, JOSEPH A | reporter.nih.gov |
| HIV Drug Resistance Database | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,908,327 | May 1, 2018 | April 30, 2028 | SHAFER, ROBERT WILLIAM | reporter.nih.gov |
| Biophysical foundations of evolutionary dynamics | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,900,407 | June 1, 2021 | September 30, 2026 | SHAKHNOVICH, EUGENE I | reporter.nih.gov |
| Carbapenemase-Stable Carbapenem Antibiotics for Treatment of Multidrug-Resistant Acinetobacter baumannii Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,877,163 | April 6, 2021 | March 31, 2027 | VAKULENKO, SERGEI | reporter.nih.gov |
| Developing broad-spectrum therapeutics against C. difficile toxins | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,852,231 | February 11, 2021 | January 31, 2027 | JIN, RONGSHENG | reporter.nih.gov |
| Optimization of novel phenotypic screening hits for treatment of Malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,843,960 | April 1, 2021 | March 31, 2027 | PHILLIPS, MARGARET A. | reporter.nih.gov |
| Mechanisms of protection against shigellosis in children | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,843,317 | June 9, 2022 | May 31, 2027 | PASETTI, MARCELA F | reporter.nih.gov |
| New antifungals targeting the synthesis of fungal sphingolipids | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,827,282 | December 1, 2015 | March 31, 2026 | DEL POETA, MAURIZIO | reporter.nih.gov |
| Population Genomic Analysis of Gut Microbial Colonization in Premature Infants | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,825,244 | July 15, 2011 | June 30, 2026 | BANFIELD, JILLIAN | reporter.nih.gov |
| Impact of early-life perturbations on pediatric microbiome maturation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,815,792 | June 8, 2021 | June 23, 2026 | DANTAS, GAUTAM | reporter.nih.gov |
| Advanced Genotypic and Phenotypic monitoring of Drug Resistant TB to Improve TB Treatment Outcomes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,809,183 | August 1, 2015 | July 31, 2030 | LARSEN, MICHELLE H | reporter.nih.gov |
| Evolution and inhibition of carbapenemase in beta-lactam resistance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,748,354 | April 6, 2021 | March 31, 2027 | CHEN, YU | reporter.nih.gov |
| Validating the Flavivirus Envelope Protein as an Antiviral Target | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,735,490 | March 1, 2020 | February 28, 2026 | YANG, PRISCILLA LI-NING | reporter.nih.gov |
| Lead Optimization of DHODH Inhibitors for Malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,721,559 | January 1, 2013 | June 30, 2028 | PHILLIPS, MARGARET A. | reporter.nih.gov |
| Improving Diagnosis, Treatment & Detection of Drug Resistance in HIV-2 Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,714,082 | June 15, 2015 | August 31, 2030 | GOTTLIEB, GEOFFREY SCOTT | reporter.nih.gov |
| Repurposing Gram-positive Antibiotics for Gram-Negative Bacteria using Antibiotic Adjuvants | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,690,863 | September 20, 2022 | July 31, 2027 | MELANDER, CHRISTIAN COREY | reporter.nih.gov |
| Mapping the genomic and molecular mechanisms of antifungal resistance in the emerging fungal pathogen Candida auris | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,661,637 | March 6, 2023 | February 29, 2028 | ROGERS, P. DAVID | reporter.nih.gov |
| The Bring BPaL2Me Trial - Comparing Nurse-Led RR-TB Treatment in Primary Care to Physician-Led, Hospital-Based RR-TB Treatment: A Cluster Randomized, Non-Inferiority Trial | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,655,506 | March 10, 2023 | February 29, 2028 | FARLEY, JASON EDWARD | reporter.nih.gov |
| An Etonogestrel/Ethinyl Estradiol/QGriffithsin (ETG/EE/QGRFT) IVR to Prevent Pregnancy and HIV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,644,121 | April 6, 2020 | August 31, 2025 | TELESHOVA, NATALIA | reporter.nih.gov |
| Engineering protease-resistant antiviral peptide inhibitors for SARS-CoV-2 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,639,039 | August 1, 2021 | July 31, 2027 | MOSCONA, ANNE | reporter.nih.gov |
| A randomized, double-blind, multi-center comparative effectiveness study of spironolactone versus doxycycline hyclate for the treatment of acne in women | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $3,635,308 | August 17, 2021 | July 31, 2027 | MARGOLIS, DAVID JOEL | reporter.nih.gov |
| DEVELOPMENT OF A VACCINE CANDIDATE FOR DRUG-RESISTANT FUNGAL INFECTIONS | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,605,418 | September 30, 2025 | June 1, 2030 | NABORS, GARY | reporter.nih.gov |
| Development of ureadepsipetides for drug-resistant infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,597,406 | December 17, 2018 | November 30, 2024 | LAFLEUR, MICHAEL | reporter.nih.gov |
| Novel pre-coital, non-hormonal multipurpose prevention technology (MPT) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,585,858 | March 20, 2020 | February 28, 2026 | ANGSANTIKUL, PAVIMOL | reporter.nih.gov |
| Inhaled tigecycline therapy for pulmonary M. abscessus infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,573,339 | June 29, 2021 | May 31, 2027 | GONZALEZ-JUARRERO, MERCEDES | reporter.nih.gov |
| Mechanism of the Fluoroquinolone Resistance Acquisition in Enterobacteria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,553,622 | April 6, 2021 | September 30, 2026 | SOKURENKO, EVGENI VENIAMINOVIC | reporter.nih.gov |
| Biophysical studies of macromolecules and molecular assemblies | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,542,462 | July 1, 2016 | July 31, 2026 | BOXER, STEVEN G. | reporter.nih.gov |
| Development of anti-LPS therapeutic antibodies for the treatment of Pseudomonas aeruginosa infections | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,521,872 | August 1, 2024 | July 31, 2029 | BARBIER, MARIETTE | reporter.nih.gov |
| V-OLA point-of-care HIV viral load monitoring and drug resistance testing | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,486,755 | June 14, 2019 | April 30, 2029 | LUTZ, BARRY RYAN | reporter.nih.gov |
| Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,483,730 | September 1, 2023 | August 31, 2028 | ROSEN, DAVID A. | reporter.nih.gov |
| Mechanisms of varied sensitivity of P. falciparum field isolates to the antimalarial drug pipeline | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,469,861 | July 1, 2025 | June 30, 2028 | ROSENTHAL, PHILIP JON | reporter.nih.gov |
| Host-mediated zinc sequestration during Acinetobacter baumannii infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,464,931 | January 15, 2013 | March 31, 2028 | SKAAR, ERIC P | reporter.nih.gov |
| Neisseria gonorrhoeae metal transporters that subvert nutritional immunity | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,458,371 | August 9, 2017 | July 31, 2027 | CORNELISSEN, CYNTHIA N | reporter.nih.gov |
| HIV Incidence and Drug Resistance Surveillance using Microdrop HIV Sequencing | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,435,250 | August 10, 2011 | May 31, 2027 | LEE, HA YOUN | reporter.nih.gov |
| Deciphering the relationship between structure, dynamics and function in helical bundle proteins | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,428,074 | May 1, 2017 | July 31, 2027 | DEGRADO, WILLIAM | reporter.nih.gov |
| Structural, mechanistic, & evolutionary characterization of tetracycline destructases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,423,406 | February 11, 2016 | April 30, 2027 | DANTAS, GAUTAM | reporter.nih.gov |
| Novel bi-specific immunotherapeutic against high-threat Gram-negative pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,410,042 | February 21, 2019 | January 31, 2025 | PERLIN, DAVID S | reporter.nih.gov |
| Chemogenomic Profiling of Plasmodium Falciparum Responses and Resistance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,402,300 | February 10, 2015 | June 30, 2027 | ADAMS, JOHN H | reporter.nih.gov |
| Microbial Community Disruption Following Topical Antimicrobial Application in Staphylococcus aureus-Affected Households | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,400,860 | May 19, 2021 | April 30, 2027 | FRITZ, STEPHANIE ANN | reporter.nih.gov |
| Characterizing Vancomycin-Resistant C. difficile Strains at Two Geographically Distinct Locations | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,395,135 | April 1, 2021 | March 31, 2027 | DARKOH, CHARLES | reporter.nih.gov |
| Chemical Biology of HIV-1 Nef | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,379,708 | September 1, 2020 | July 31, 2029 | SMITHGALL, THOMAS E. | reporter.nih.gov |
| Development of Gene-Silencing Therapeutics for Pseudomonas aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,379,247 | August 1, 2019 | July 31, 2025 | GREENBERG, DAVID ELIHU | reporter.nih.gov |
| Structural basis for activity of and resistance to HIV integrase inhibitors | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,374,115 | September 25, 2017 | August 31, 2027 | LYUMKIS, DMITRY | reporter.nih.gov |
| Inhalation Therapy Platform for Coronavirus Infection Treatment | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,373,230 | September 17, 2021 | August 31, 2026 | STAYTON, PATRICK S. | reporter.nih.gov |
| Commensal control of C. difficile virulence | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,372,908 | February 1, 2021 | January 31, 2027 | BRY, LYNN | reporter.nih.gov |
| A Synthetic Platform for Non-Antibiotic Eradication of Bacterial Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,360,000 | September 30, 2019 | July 31, 2025 | HERMAN, CHRISTOPHE | reporter.nih.gov |
| Development of a Novel Oral Antibiotic for the Treatment of Drug Resistant Gonorrhea | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,356,811 | August 8, 2022 | July 31, 2026 | WANG, LAURENE | reporter.nih.gov |
| Deciphering fundamental biological processes involving protein-nucleic acid interactions at the molecular level | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,354,677 | January 1, 2019 | December 31, 2027 | SCHUMACHER, MARIA | reporter.nih.gov |
| Developing Inhibitors of Seasonal and Pandemic Influenza Viruses | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,352,410 | August 18, 2025 | July 31, 2029 | PLEMPER, RICHARD K. | reporter.nih.gov |
| Targeting Clostridioides difficile with microbiome-sparing, resistant-proof anti-toxins | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,343,705 | April 1, 2021 | March 31, 2026 | SCHRAMM, VERN L. | reporter.nih.gov |
| Cross-Kingdom Vaccine Targeting Healthcare-Associated Priority Pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,343,171 | January 9, 2019 | December 31, 2024 | IBRAHIM, ASHRAF S. | reporter.nih.gov |
| Second-Generation Novel Liver Stage Active Antimalarials | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,320,110 | April 1, 2021 | March 31, 2027 | KELLY, JANE X | reporter.nih.gov |
| Development of Therapeutic Candidates for Antibiotic Resistant Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,318,955 | September 24, 2025 | February 7, 2029 | KIM, PAUL JOON | reporter.nih.gov |
| Mapping host-microbe-metabolite interactions in 3D to find diet-derived enhancers of immunity | NIH | National Center for Complementary & Integrative Health | 2021 to 2023 | $3,318,000 | September 30, 2019 | July 31, 2024 | KNIGHT, ROB | reporter.nih.gov |
| Advanced development of a viral entry inhibitor as a therapeutic for arenavirus hemorrhagic fever | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $3,315,958 | January 1, 2019 | December 31, 2023 | AMBERG, SEAN M | reporter.nih.gov |
| Defining the resistome in P. falciparum: evolution and mechanism | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,309,597 | November 2, 2022 | October 31, 2027 | WINZELER, ELIZABETH A | reporter.nih.gov |
| Dynamics and Regulation of Peptidoglycan Cell Wall Synthesis in the Superbug Streptococcus pneumoniae | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,298,698 | September 5, 2019 | June 30, 2029 | WINKLER, MALCOLM E. | reporter.nih.gov |
| Small molecule-induced degradation of dengue proteins as an antiviral strategy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,293,894 | July 23, 2020 | June 30, 2025 | YANG, PRISCILLA LI-NING | reporter.nih.gov |
| Antibiotics : Studies on the Biological Mechanisms of Antibiotics | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,289,320 | August 5, 2025 | July 31, 2030 | KAHNE, DANIEL | reporter.nih.gov |
| Genomic Epidemiology of Campylobacter to Improve Disease Control in Low and Middle Income Countries | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,270,801 | March 15, 2021 | February 28, 2027 | KOSEK, MARGARET N | reporter.nih.gov |
| Informing Drug Synergy: Investigating Mycobacterial Membrane Protein Structure and Function | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,262,539 | August 1, 2025 | July 31, 2029 | REGO, ELIZABETH HESPER | reporter.nih.gov |
| Spectinomycin analogs for NTM infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,229,019 | September 17, 2020 | August 31, 2025 | LEE, RICHARD E. | reporter.nih.gov |
| Decoding the clinical impact of the recent evolution of metronidazole resistance on Clostridium difficile infection. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,220,673 | August 20, 2018 | January 31, 2028 | HURDLE, JULIAN G | reporter.nih.gov |
| Real-Time Detection of Staphylococcus aureus Transmission in Hospital Settings | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,210,845 | July 25, 2025 | June 30, 2029 | SHOPSIN, BO | reporter.nih.gov |
| Drivers of strain-specific and strain-transcendent antimalarial immunity in childhood | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,209,021 | June 17, 2020 | May 31, 2026 | GREENHOUSE, BRYAN R | reporter.nih.gov |
| Exploitation of multiple heteroresistance for effective antibiotic combination therapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,205,931 | July 1, 2020 | June 30, 2026 | WEISS, DAVID S | reporter.nih.gov |
| Development and Field Testing of a Novel Reservoir Targeted Antibiotic Against Borrelia burgdorferi | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,201,446 | May 15, 2020 | April 30, 2026 | HU, LINDEN T | reporter.nih.gov |
| Dual Targeting of Mtb Resistance Mechanisms | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,194,513 | September 22, 2020 | August 31, 2025 | GRUNDNER, CHRISTOPH | reporter.nih.gov |
| Alanyl-glutamine supplementation of standard treatment for C. difficile infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,184,912 | July 13, 2020 | June 30, 2026 | WARREN, CIRLE ALCANTARA | reporter.nih.gov |
| Development of human adaptive immunity to Staphylococcus aureus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,170,541 | March 5, 2021 | February 28, 2027 | BUBECK WARDENBURG, JULIANE | reporter.nih.gov |
| Ultra-potent HIV capsid inhibitors | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,168,060 | September 21, 2020 | August 31, 2025 | KVARATSKHELIA, MAMUKA | reporter.nih.gov |
| Development of peptide nucleic acid antibiotics | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,164,488 | February 10, 2021 | January 31, 2025 | ARYA, DEV PRIYA | reporter.nih.gov |
| Launching HBV with RNA to assess antiviral resistance and explore fundamental aspects of virus-host biology | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,156,556 | February 10, 2020 | April 30, 2030 | RICE, CHARLES M | reporter.nih.gov |
| Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and Adults | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,153,883 | September 24, 2018 | October 31, 2028 | HEYSELL, SCOTT K | reporter.nih.gov |
| Plasmodium Protein Kinase Focused Antimalarials Discovery | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,144,589 | July 11, 2022 | June 30, 2027 | CHAKRABARTI, DEBOPAM | reporter.nih.gov |
| Vesicle-mediated drug resistance of Candida albicans biofilm | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,140,049 | June 15, 2008 | August 31, 2029 | ANDES, DAVID R | reporter.nih.gov |
| Transport Mechanisms and Inhibition of Efflux Pumps in Pathogenic Organisms | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,135,598 | December 1, 2021 | August 3, 2025 | TRAASETH, NATHANIEL J. | reporter.nih.gov |
| Genomics-Assisted Antibiotic Discovery from Unprecedented Microbes of the Great Salt Lake | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,135,301 | July 12, 2021 | April 30, 2027 | WINTER, JACLYN MARIE | reporter.nih.gov |
| Optimizing anti-microbial immunity by targeting Sts-1 | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,125,627 | July 23, 2025 | June 30, 2029 | CARPINO, NICHOLAS A | reporter.nih.gov |
| The Doxy-PEP Impact Study: a multi-city US longitudinal cohort to evaluate doxy-PEP field effectiveness, investigate associated antimicrobial resistance, and establish doxy-PEP to need ratios | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,121,386 | July 18, 2024 | June 30, 2029 | LUETKEMEYER, ANNE FREY | reporter.nih.gov |
| Pay-it-forward gonorrhea testing among men who have sex with men: The PIONEER pragmatic randomized controlled trial | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,115,633 | March 19, 2021 | February 28, 2027 | TUCKER, JOSEPH DAVID | reporter.nih.gov |
| Determinants of H. influenzae Virulence in Otitis Media | NIH | National Institute on Deafness and Other Communication Disorders | 2021 to 2025 | $3,109,258 | September 30, 1999 | December 31, 2026 | GOODMAN, STEVEN D | reporter.nih.gov |
| Novel Combination Therapies to Combat Hypermutable Carbapenem-Resistant P. aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,106,846 | May 24, 2022 | April 30, 2027 | TSUJI, BRIAN | reporter.nih.gov |
| Membrane-active quinoline and quinazoline antibacterials that target Gram positive pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,102,056 | March 1, 2020 | February 28, 2026 | CHEUNG, AMBROSE LIN YAU | reporter.nih.gov |
| Immunological characterization of rationally-designed vaccines against plague in mice and non-human primate models | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,082,735 | February 1, 2021 | July 31, 2026 | CHOPRA, ASHOK K | reporter.nih.gov |
| Novel Strategies for Antibiotic Combinations to Combat Gram-negative Superbugs | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,081,358 | December 20, 2019 | November 30, 2025 | TSUJI, BRIAN | reporter.nih.gov |
| Novel Therapeutics to Target Parasite Cytochrome bc1 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,077,845 | July 15, 2012 | June 30, 2027 | RISCOE, MICHAEL KEVIN | reporter.nih.gov |
| Use of De Novo Synthesis Approaches and Structure-guided Design to Optimize Therapeutic Properties of Streptothricin Class Antimicrobials | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,077,792 | September 23, 2020 | August 31, 2025 | KIRBY, JAMES E | reporter.nih.gov |
| Cumulative burden of Chlamydia trachomatis and Mycoplasma genitalium in the US: implications for screening guidelines and antimicrobial resistance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,074,527 | May 1, 2021 | April 30, 2027 | MANHART, LISA E | reporter.nih.gov |
| Molecular basis of antimalarial drug resistance in Plasmodium vivax | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,064,807 | March 18, 2022 | February 28, 2027 | DURAISINGH, MANOJ T | reporter.nih.gov |
| Antifungal antagonism as a cause of treatment failure for invasive mycoses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,062,575 | April 1, 2021 | March 31, 2027 | PALMER, GLEN | reporter.nih.gov |
| Development of novel anti-Neisseria gonorrhoeae therapeutic agents | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,055,792 | August 12, 2022 | July 31, 2027 | FLAHERTY, DANIEL PATRICK | reporter.nih.gov |
| Form with function: Rapid phenotypic carbapenemase testing to improve detection of carbapenemase-producing organisms | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,055,197 | July 25, 2025 | June 30, 2029 | MYERS, DAVID RICHARD | reporter.nih.gov |
| Direct-from-specimen identification of pathogens common in endocarditis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,051,028 | January 4, 2018 | December 31, 2026 | SINGER, ALON | reporter.nih.gov |
| Direct detection and identification of antimicrobial resistance genes in bloodstream infections | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $3,050,000 | August 9, 2022 | July 31, 2025 | SINGER, ALON | reporter.nih.gov |
| TASK D10: A PHASE 1 TRIAL TO EVALUATE A TREATMENT FOR CLOSTRIDIOIDES DIFFICILE | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,033,881 | January 14, 2022 | January 13, 2032 | SPITZ, ROBERT | reporter.nih.gov |
| Therapeutic vaccination to augment stringent response-specific T-cell immunity to MTB persisters | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,027,518 | March 17, 2020 | February 28, 2025 | KARAKOUSIS, PETROS C | reporter.nih.gov |
| Biomimetic Macrophage Membrane-Coated Nanosponges: A Novel Therapeutic for Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii Hospital-Associated Pneumonia | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,027,494 | July 1, 2023 | June 30, 2028 | NIZET, VICTOR | reporter.nih.gov |
| Host Directed Orynotide for MDR Gram Negative Bacterial Infections | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,025,760 | July 21, 2023 | June 30, 2028 | SCHAAL, JUSTIN BLAINE | reporter.nih.gov |
| Novel Antimalarials from Fungi | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,025,049 | May 18, 2020 | April 30, 2026 | CHAKRABARTI, DEBOPAM | reporter.nih.gov |
| Measuring Intralesional Drug Exposures in Cavitary TB using Noninvasive In Vivo PET Imaging | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,024,535 | July 1, 2020 | June 30, 2025 | JAIN, SANJAY | reporter.nih.gov |
| Mechanistic basis of bacteriophages for the decolonization of vancomycin resistant enterococci in the intestine | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,022,123 | September 14, 2018 | July 31, 2028 | DUERKOP, BRECK A | reporter.nih.gov |
| MAb Passive Vaccination against Acinetobacter baumannii | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,021,383 | September 25, 2017 | August 31, 2027 | SPELLBERG, BRAD J | reporter.nih.gov |
| Adaptation of vancomycin-resistant enterococci during bloodstream infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,020,097 | June 3, 2022 | May 31, 2027 | VAN TYNE, DARIA N | reporter.nih.gov |
| Discovery through chemical synthesis of antibiotics effective against modern bacterial pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,017,163 | February 10, 2022 | January 31, 2027 | MYERS, ANDREW G | reporter.nih.gov |
| Symbiotic-based discovery of turbinmicin, a safe and selective antifungal against resistant fungi | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,015,316 | March 4, 2022 | February 28, 2027 | ANDES, DAVID R | reporter.nih.gov |
| Uncovering the rules of gut microbiome strain transmission | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,013,179 | January 20, 2020 | December 31, 2028 | FAITH, JEREMIAH JAMES | reporter.nih.gov |
| Dietary Fiber-Microbiome Interactions: Elucidating Mechanisms to Suppress Multi-Drug Resistant Organisms in the Human Gut | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,012,181 | September 10, 2025 | August 31, 2029 | VENTURELLI, OPHELIA | reporter.nih.gov |
| The impact of bacteriophage therapy on wound infection dynamics | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,006,418 | February 2, 2022 | January 31, 2027 | WOZNIAK, DANIEL J | reporter.nih.gov |
| Evaluating darobactins as antimicrobial agents | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,000,880 | April 1, 2021 | March 31, 2026 | LEWIS, KIM | reporter.nih.gov |
| Broad spectrum β-lactamase inhibitors employing a Trojan horse mechanism to rescue β-lactams against multidrug-resistant Pseudomonas aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $3,000,000 | March 10, 2022 | February 28, 2026 | LIU, BIN | reporter.nih.gov |
| Regional Prospective Observational Research in Tuberculosis (RePORT) – Brazil Network | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,000,000 | January 2, 2023 | December 31, 2027 | STERLING, TIMOTHY R | reporter.nih.gov |
| Therapy and Prophylaxis for Genital Tract Infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,000,000 | February 1, 2013 | July 31, 2026 | AUCI, DOMINICK | reporter.nih.gov |
| Development of a Dual-Targeting ClpP Activating Antibiotic | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,999,619 | September 1, 2023 | August 31, 2026 | LAFLEUR, MICHAEL | reporter.nih.gov |
| Aminoglycosides with reduced ototoxicity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,999,400 | August 1, 2020 | February 28, 2026 | ARYA, DEV PRIYA | reporter.nih.gov |
| Commercialization Readiness Pilot (CRP) program support for: Direct-from-specimen identification of pathogens common in endocarditis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,997,234 | June 20, 2023 | May 31, 2027 | SINGER, ALON | reporter.nih.gov |
| Development of MRS-2541, a methionyl-tRNA synthetase inhibitor, for Gram positive bacterial infections. | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,995,956 | August 3, 2017 | March 31, 2026 | LIPKA, ELKE | reporter.nih.gov |
| Improving diagnostic sensitivity for difficult-to-lyse microbial samples with nanodroplet technology | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,995,731 | August 3, 2020 | April 30, 2026 | KASOJI, SANDEEP | reporter.nih.gov |
| Lab-on-a-Film Multiplexed Test for Respiratory Mycobacterial Infections | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,995,164 | April 21, 2021 | July 31, 2025 | COONEY, CHRISTOPHER GERARD | reporter.nih.gov |
| Personalized Antimicrobial Combinations to Combat Resistance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,994,030 | August 15, 2018 | June 30, 2029 | TAM, VINCENT H | reporter.nih.gov |
| Heterocyclic Inhibitors of QcrB as Novel Drugs for Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,992,852 | December 13, 2019 | November 30, 2024 | HANNAN, THOMAS JOSEPH | reporter.nih.gov |
| Ototoxicity of modified aminoglycosides | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,989,181 | July 11, 2022 | June 30, 2026 | STORY, SANDRA PAIGE | reporter.nih.gov |
| Teixobactin Development for Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,988,753 | September 1, 2022 | August 31, 2025 | HUGHES, DALLAS | reporter.nih.gov |
| A New Approach to Treat Prosthetic Joint Infections with a ClpP Activating Antibiotic | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,986,246 | March 8, 2021 | February 28, 2025 | LAFLEUR, MICHAEL | reporter.nih.gov |
| Novel hand hygiene product to remove Clostridioides difficile spores | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,981,889 | March 9, 2023 | February 28, 2027 | LABIB, MOHAMED E | reporter.nih.gov |
| Decreasing antibiotic prescribing in acute respiratory infections through implementation of nurse driven clinical decision support | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,980,355 | April 15, 2014 | November 30, 2025 | MANN, DEVIN M | reporter.nih.gov |
| Small molecules for perturbing iron homeostasis in bacterial biofilms | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,979,765 | February 15, 2022 | January 31, 2027 | RIVERA, MARIO | reporter.nih.gov |
| Exploring polyamine toxicity and resistance in epidemic bacterial skin pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $2,976,652 | August 1, 2025 | July 31, 2029 | RICHARDSON, ANTHONY R. | reporter.nih.gov |
| Rapid antimicrobial susceptibility testing directly from urine specimens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,974,719 | April 1, 2021 | March 31, 2024 | BURG, LAWRENCE | reporter.nih.gov |
| Establishing a Gram-Negative Permeation Rule Set Leveraging a Unique Small Molecule Library | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,971,055 | August 22, 2018 | July 31, 2024 | BOYD, STEVEN ARMEN | reporter.nih.gov |
| Molecular Clonality of Uropathogenic E. Coli | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,968,549 | November 19, 2013 | April 30, 2026 | SOKURENKO, EVGENI VENIAMINOVIC | reporter.nih.gov |
| Multivalent Adjuvant Immunization to Prevent Hospital Acquired Infections | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,968,040 | February 10, 2020 | May 31, 2025 | SPELLBERG, BRAD J | reporter.nih.gov |
| Optimization of antimalarials targeting multiple life stages of the parasite | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,967,032 | August 4, 2021 | July 31, 2027 | CARLIER, PAUL R | reporter.nih.gov |
| Development of a PO-administered beta-lactam-tarocin combination agent to treat methicillin susceptible and methicillin resistant Staphylococci | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,965,088 | February 5, 2018 | June 30, 2026 | ROEMER, TERRY | reporter.nih.gov |
| Advancing Fast-acting Antimalarials that Disrupt Na+ Homeostasis in Parasites | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,964,364 | August 12, 2020 | July 31, 2026 | VAIDYA, AKHIL B | reporter.nih.gov |
| Pharmacological insights into antimalarial exposure, clinical outcomes, and drug resistance in Africa | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,963,157 | February 10, 2015 | April 30, 2026 | ROSENTHAL, PHILIP JON | reporter.nih.gov |
| Beta-Lactam Resistance Mechanisms of Staphylococcus aureus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,961,834 | January 1, 2013 | December 31, 2027 | MOBASHERY, SHAHRIAR | reporter.nih.gov |
| Artemisinin Resistance in Africa: its emergence and evolution in Rwanda | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,954,668 | August 5, 2021 | July 31, 2025 | BAILEY, JEFFREY A. | reporter.nih.gov |
| Staphylococcus aureus SPREAD (S. aureus Study of Prevalence Resistance and Environmental Dissemination) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,952,734 | July 1, 2022 | June 30, 2027 | DAVID, MICHAEL ZDENEK | reporter.nih.gov |
| Handheld and population-based sequencing for rapid detection of new and repurposed drug resistance in M. tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,952,078 | March 1, 2025 | February 28, 2027 | METCALFE, JOHN ZAPATA | reporter.nih.gov |
| Rapid AST through Metabolic Imaging at Single Cell Level | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,949,272 | December 1, 2018 | June 30, 2027 | CHENG, JI-XIN | reporter.nih.gov |
| Understanding resistance and tolerance to nitroimidazoles in Mycobacterium tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $2,944,529 | July 23, 2025 | June 30, 2029 | SCHNAPPINGER, DIRK | reporter.nih.gov |
| Development of a broad spectrum teixobactin-lipopeptide hybrid for the treatment of lung infections caused by pan-drug resistant ‘superbugs’ | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,944,400 | June 21, 2022 | May 31, 2027 | RAO, GAURI G | reporter.nih.gov |
| Investigating bacterial contributions to TB treatment response: a focus on in-host pathogen dynamics | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,943,133 | September 22, 2020 | August 31, 2025 | FARHAT, MAHA | reporter.nih.gov |
| Rapid dissection of the biosynthesis of antiMRSA antibiotics produced in co-culture by extremophilic fungi through the development of Fungal Artificial Chromosomes | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,942,798 | July 1, 2022 | December 31, 2025 | WU, CHENGCANG CHARLES | reporter.nih.gov |
| An automated, scalable, and rapid AST system for Gonorrhea STIs | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,934,394 | January 15, 2021 | December 31, 2023 | SWIGER, ROY R | reporter.nih.gov |
| Comparative resistomics of Gram-negative bacterial pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,934,000 | January 10, 2022 | December 31, 2026 | OSTERMAN, ANDREI L | reporter.nih.gov |
| FabI Inhibitors as Potent, Gut Microbiome-Sparing Antibiotics | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,933,391 | June 26, 2023 | May 31, 2028 | HERGENROTHER, PAUL | reporter.nih.gov |
| Commercialization of PANDAA qDx for rapid drug resistance genotyping of protease inhibitor ART failures in resource-limited settings. | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,932,453 | January 17, 2017 | July 31, 2025 | MACLEOD, IAIN JAMES | reporter.nih.gov |
| Identification and analysis of compensatory mutations that support the evolution of antibiotic resistance in Neisseria gonorrhoeae | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,923,499 | July 17, 2020 | May 19, 2025 | GRAD, YONATAN H | reporter.nih.gov |
| Advancing Apoptosis-Inducing Agents as Host-Directed Therapy for TB | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $2,922,220 | September 3, 2025 | August 31, 2029 | KARAKOUSIS, PETROS C | reporter.nih.gov |
| Genomic and geospatial analyses of malaria parasite migration to inform elimination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,915,635 | March 1, 2020 | February 28, 2026 | HARRISON, SHANNON TAKALA | reporter.nih.gov |
| Targeting Membrane Transport Steps in Cell Envelope Assembly | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,914,356 | May 21, 2020 | July 31, 2025 | KAHNE, DANIEL | reporter.nih.gov |
| A Serological Assay for Neutralizing Antitoxin Response in Patients with Clostridioides difficile Infection (Phase II) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,911,659 | January 20, 2018 | July 31, 2026 | YANG, ZHIYONG | reporter.nih.gov |
| RNAi-dependent epimutation roles in antimicrobial drug resistance and pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,911,488 | July 1, 2022 | June 30, 2027 | HEITMAN, JOSEPH | reporter.nih.gov |
| Changing Cultures in Sepsis: Rapid single-cell pathogen identification and antibiotic susceptibility testing directly from whole blood | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,910,960 | June 15, 2020 | May 31, 2026 | YANG, SAMUEL | reporter.nih.gov |
| Leveraging PfCRT Structure to Discern Function and Predict Emergence of Drug-Resistant Malaria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,908,665 | July 1, 2019 | November 30, 2029 | MANCIA, FILIPPO | reporter.nih.gov |
| Optimization, Manufacturing and Testing of a Lead Therapeutic Bacteriophage Cocktail for the Treatment of Antibiotic-Resistant Klebsiella pneumoniae Infections | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,908,260 | July 21, 2023 | June 30, 2028 | FOUTS, DERRICK E | reporter.nih.gov |
| Ultraviolet Photodissociation Mass Spectrometry for Characterization of Biological Molecules | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,899,234 | January 1, 2021 | December 31, 2026 | BRODBELT, JENNIFER S. | reporter.nih.gov |
| Mechanism and activity of beta-lactam resistant enzymes in E. faecium and E. faecalis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,896,372 | August 11, 2025 | July 31, 2030 | RICE, LOUIS B. | reporter.nih.gov |
| Development of Therapeutic Products for Antibiotic Resistant Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2021 | $2,887,773 | July 1, 2020 | May 31, 2022 | TOMMASI, RUBEN | reporter.nih.gov |
| Proteomics-Driven Reverse Vaccinology for Gonorrhea | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,883,482 | February 10, 2022 | January 31, 2027 | SIKORA, ALEKSANDRA ELZBIETA | reporter.nih.gov |
| Malaria transmission blocking through mosquito contact with treated surfaces | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,877,675 | February 4, 2020 | January 31, 2026 | CATTERUCCIA, FLAMINIA | reporter.nih.gov |
| The role of enteric pathogens and antimicrobial resistance in driving clinical and nutritional deterioration, and azithromycin's potential effect, among children discharged from hospital in Kenya | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,876,978 | March 15, 2020 | February 28, 2026 | PAVLINAC, PATRICIA | reporter.nih.gov |
| Clostridioides difficile Zinc-binding PBPs as anti-sporulation targets | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $2,872,722 | August 1, 2025 | July 31, 2029 | CHEN, YU | reporter.nih.gov |
| Antimicrobial Resistance and Horizontal Gene Transfer in the Human Gut Microbiome in Response to an Antibiotic | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,871,429 | June 1, 2020 | May 31, 2026 | RELMAN, DAVID A. | reporter.nih.gov |
| Emergence of bedaquiline and clofazimine resistance after interruption of drug-resistant TB therapy in a high HIV prevalence setting | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,868,143 | December 26, 2019 | November 30, 2026 | BRUST, JAMES C M | reporter.nih.gov |
| Precision Dosing for Critically Ill Children | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2025 | $2,860,284 | August 17, 2022 | April 30, 2027 | NEELY, MICHAEL N. | reporter.nih.gov |
| A New Class of Broad-Spectrum Antibacterial Agents to Treat Multi-Drug Resistant Pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,858,436 | July 21, 2023 | June 30, 2027 | SEBAHAR, PAUL | reporter.nih.gov |
| Single dose azithromycin to prevent cholera in children | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $2,854,798 | August 5, 2021 | May 31, 2027 | HARRIS, JASON B | reporter.nih.gov |
| Development of a Broad-Spectrum Inhibitor against Seasonal and Highly-Pathogenic Influenza Viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,853,123 | January 8, 2019 | December 31, 2025 | PLEMPER, RICHARD K. | reporter.nih.gov |
| Strengthening evidence on optimal multidrug-resistant tuberculosis treatment regimens through improved epidemiologic methods | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,850,504 | May 1, 2020 | April 30, 2026 | FRANKE, MOLLY FORREST | reporter.nih.gov |
| Development of PTLS-209 for treatment for giardiasis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,849,878 | July 12, 2022 | June 30, 2027 | PADIA, JANAK K | reporter.nih.gov |
| Design, Syntheses and Studies of Novel Antituberculosis Agents | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,840,145 | September 1, 2021 | August 31, 2026 | MILLER, MARVIN J | reporter.nih.gov |
| Differentially Culturable Tubercle Bacteria: The missing link in TB Transmission? | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,838,851 | September 1, 2019 | August 31, 2025 | KANA, BAVESH DAVANDRA | reporter.nih.gov |
| Drug Resistance Genotypic and Phenotypic Correlates of Efavirenz and Dolutegravir based Treatment Outcomes across Non-B HIV-1 subtypes | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,818,924 | July 10, 2019 | June 30, 2025 | FRENKEL, LISA M | reporter.nih.gov |
| Molecular mechanism of cephalosporin resistance of N. gonorrhoeae conferred by mutated PBP2 | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,818,329 | March 10, 2022 | February 28, 2027 | DAVIES, CHRISTOPHER | reporter.nih.gov |
| Combating Antibiotic Resistance Into the Next Generation (CARING) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,817,471 | July 1, 1976 | December 31, 2026 | NIZET, VICTOR | reporter.nih.gov |
| Virus-host interactions and microbial ecology | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,803,865 | May 6, 2016 | April 30, 2027 | HARSHEY, RASIKA M | reporter.nih.gov |
| Mechanisms of MRSA intestinal colonization | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,795,502 | January 17, 2020 | December 31, 2025 | SHOPSIN, BO | reporter.nih.gov |
| Next-generation phenotypic antimicrobial susceptibility test platform: rapid resultsand comprehensive menus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,794,217 | January 1, 2018 | August 31, 2024 | STERN, ERIC | reporter.nih.gov |
| Discovery of long-acting, chemoprotective antimalarial compounds | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,791,259 | March 25, 2020 | February 28, 2026 | WINZELER, ELIZABETH A | reporter.nih.gov |
| Mapping Drug Resistance Genes in Plasmodium falciparum | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,782,422 | September 1, 2000 | November 30, 2027 | ANDERSON, TIM J | reporter.nih.gov |
| Charge matters: Pursuing the most common, and least understood molecular interactions in cells | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,763,979 | December 1, 2020 | November 30, 2026 | SUEL, GUROL MEHMET | reporter.nih.gov |
| Dynamics and evolution of synthetic and natural gene regulatory networks | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,761,740 | April 1, 2017 | August 31, 2027 | BALAZSI, GABOR | reporter.nih.gov |
| Identifying Optimal Antibiotic Regimens to Treat Urinary Tract Infections During Pregnancy | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2022 to 2025 | $2,760,230 | August 1, 2022 | April 30, 2027 | BUTLER, ANNE MOBLEY | reporter.nih.gov |
| Focused Ultrasound Treatment of Skin and Soft Tissue Abscesses | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2025 | $2,757,884 | June 15, 2022 | May 31, 2027 | MATULA, THOMAS | reporter.nih.gov |
| A systems approach to manipulate microbial adaptation to structured environments | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,756,214 | June 7, 2019 | May 31, 2025 | BALIGA, NITIN S | reporter.nih.gov |
| Proline homeostasis: a novel mediator of drug tolerance in Plasmodium falciparum | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,742,796 | April 1, 2020 | March 31, 2025 | MAZITSCHEK, RALPH | reporter.nih.gov |
| Mechanism of Colonization Resistance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,739,660 | August 20, 2014 | March 31, 2026 | BAUMLER, ANDREAS J | reporter.nih.gov |
| Novel, low corrosion, bio-compatible disinfectant with biofilm and residual efficacy | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,735,315 | August 5, 2020 | August 31, 2027 | NKEMNGONG, CARINE | reporter.nih.gov |
| Poor Treatment Response and Outcomes in Bedaquiline-Based Treatment Regimens for Drug-Resistant Tuberculosis in South Africa | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,735,126 | April 1, 2021 | March 31, 2027 | VAN DER HEIJDEN, YURI F. | reporter.nih.gov |
| Systems-based pharmacologic modelling to elucidate beta-lactam clinical pharmacodynamics and define optimal dosing regimens in severe pneumonia | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,734,140 | July 11, 2022 | June 30, 2027 | RHODES, NATHANIEL JAMES | reporter.nih.gov |
| The Cell Envelope of the Multi-Drug Resistant Pathogen Acinetobacter baumannii | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,733,570 | February 25, 2020 | January 31, 2030 | TRENT, MICHAEL STEPHEN | reporter.nih.gov |
| Combination host-directed and antibacterial therapy for pulmonary intracellular infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,715,913 | November 13, 2017 | June 30, 2029 | STAYTON, PATRICK S. | reporter.nih.gov |
| Metagenomic profiling of urinary cell-free DNA to monitor urinary tract infection after kidney transplantation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,705,917 | March 10, 2020 | February 28, 2026 | DE VLAMINCK, IWIJN | reporter.nih.gov |
| Fecal Microbiota Transplant National Registry | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,705,877 | August 4, 2016 | April 30, 2027 | WU, GARY D. | reporter.nih.gov |
| Development of Inhaled CPZEN-45 For Tuberculosis Therapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,694,338 | March 1, 2019 | February 28, 2025 | SEVERYNSE-STEVENS, DIANA M | reporter.nih.gov |
| O-polysaccharide (OPS)-IpaB Conjugate Vaccine to Prevent Shigellosis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,693,804 | June 1, 2023 | May 31, 2028 | PASETTI, MARCELA F | reporter.nih.gov |
| Improving rapid phenotypic drug susceptibility testing for drug resistant tuberculosis in high-burden areas | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,692,722 | April 6, 2023 | August 8, 2025 | TORRELLES, JORDI B | reporter.nih.gov |
| Towards rapid measurement of antibiotics in critical care setting | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2025 | $2,687,863 | September 1, 2022 | May 31, 2027 | STOJANOVIC, MILAN N | reporter.nih.gov |
| Development of HIV capsid-targeting antivirals that affect immune response by modulating capsid stability and have improved resistance profiles | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,680,982 | March 16, 2016 | May 31, 2027 | SARAFIANOS, STEFAN G | reporter.nih.gov |
| Macrorecombination in isolated cell pairs via natural genetic transformation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,657,698 | May 21, 2021 | April 30, 2027 | EDDINGTON, DAVID | reporter.nih.gov |
| Mycobacterial DNA repair and mutagenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,655,624 | February 1, 2005 | May 31, 2025 | GLICKMAN, MICHAEL S | reporter.nih.gov |
| A high-performance and versatile technology for precision microbiome engineering | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2024 | $2,652,300 | September 1, 2021 | May 31, 2026 | WANG, HARRIS H | reporter.nih.gov |
| Monoclonal Antibody to Combat Pseudomonas Aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,646,807 | August 15, 2023 | July 31, 2028 | GOLDBERG, JOANNA B | reporter.nih.gov |
| Broad spectrum Shigella subunit vaccine based on conserved proteins | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,645,606 | February 4, 2021 | January 31, 2027 | PASETTI, MARCELA F | reporter.nih.gov |
| Non-cyp51A-mutation Mediated Triazole Resistance in Aspergillus fumigatus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,634,208 | March 1, 2020 | February 28, 2026 | FORTWENDEL, JARROD R. | reporter.nih.gov |
| Discovery of Antibiotics from Soil Microbiomes Using Metagenomics | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,627,250 | May 1, 2017 | August 31, 2028 | BRADY, SEAN F | reporter.nih.gov |
| Resistance of Malaria Parasites to Artemisinin-Based Combination Therapies in Uganda | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,627,211 | August 1, 2008 | August 31, 2025 | ROSENTHAL, PHILIP JON | reporter.nih.gov |
| Plasma-based therapies for bone infection: A tripartite USA/Northern Ireland/Republic of Ireland consortium | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2021 to 2025 | $2,623,263 | February 1, 2020 | November 30, 2026 | FREEMAN, THERESA A | reporter.nih.gov |
| An Integrated In Vitro 3D Model of Human Bone Marrow and Peripheral Infection | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2024 | $2,620,380 | September 15, 2021 | May 31, 2026 | GEORGE, STEVEN CARL | reporter.nih.gov |
| Rapid fungal identification and antifungal susceptibility testing through quantitative, multiplexed RNA detection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,619,232 | July 1, 2020 | June 30, 2026 | BHATTACHARYYA, ROBY PAUL | reporter.nih.gov |
| Using the Mycobacterium tuberculosis Genome to Predict Tuberculosis Pathology, Drug Resistance Acquisition and Identify Community Transmission Sites | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,610,785 | April 15, 2020 | March 31, 2026 | GILMAN, ROBERT H | reporter.nih.gov |
| Structural Mechanisms of Clostridioides difficile pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,592,810 | May 15, 2011 | April 30, 2026 | LACY, DANA BORDEN | reporter.nih.gov |
| A multivalent O-antigen bioconjugate vaccine for the prevention of Klebsiella pneumoniae infections | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,591,387 | July 15, 2022 | July 31, 2027 | HARDING, CHRISTIAN | reporter.nih.gov |
| A randomized controlled trial of a novel, evidence-based algorithm for managing lower respiratory tract infection in a resource-limited setting | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,587,582 | August 1, 2025 | July 31, 2027 | TILLEKERATNE, GAYANI | reporter.nih.gov |
| Innate Immune Clearance of Host-Adapted Pulmonary Pathogens | NIH | National Heart, Lung, and Blood Institute | 2021 to 2023 | $2,586,182 | January 11, 2017 | November 30, 2024 | PRINCE, ALICE S | reporter.nih.gov |
| Cell Envelope Biogenesis in Clostridioides difficile | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,582,880 | June 1, 2021 | May 31, 2027 | ELLERMEIER, CRAIG D | reporter.nih.gov |
| Phenylacetic acid catabolism, a novel stress-response pathway in Acinetobacter baumannii | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,582,422 | May 12, 2022 | April 30, 2027 | FELDMAN, MARIO | reporter.nih.gov |
| Mechanisms underlying bacterial sensitivity to host-targeted drugs | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,581,834 | June 10, 2022 | May 31, 2027 | MITCHELL, AMIR | reporter.nih.gov |
| Microbial Ecology-Guided Discovery of Antibacterial Drugs | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,576,398 | February 7, 2022 | January 31, 2027 | SCHMIDT, ERIC W | reporter.nih.gov |
| A multi-level genomic and spatial analysis of MRSA transmission | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,572,708 | March 11, 2020 | February 28, 2027 | POPOVICH, KYLE JEANNE | reporter.nih.gov |
| Rapid, Breath Volatile Metabolite-Based Diagnosis, Species Identification, and Antibiotic Resistance Profiling in Bacterial Pneumonia | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,571,160 | February 15, 2023 | January 31, 2028 | KOO, SOPHIA | reporter.nih.gov |
| Novel Mechanisms of Protein Homeostasis by the Molecular Chaperone DnaK | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $2,543,522 | September 3, 2025 | August 31, 2029 | GROISMAN, EDUARDO | reporter.nih.gov |
| Defining the Role of PfCRT and PfMDR1 as Pleiotropic Mediators of Plasmodium falciparum Multidrug Resistance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,538,591 | August 1, 2001 | January 31, 2028 | FIDOCK, DAVID A | reporter.nih.gov |
| Integration of heme acquisition and signaling in Gram-negative pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,538,014 | April 1, 2021 | March 31, 2026 | WILKS, ANGELA | reporter.nih.gov |
| Hybrid Antibiotics for Persistent Infections | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,536,284 | September 26, 2023 | July 31, 2028 | LEE, RICHARD E. | reporter.nih.gov |
| PrEP and dPEP: Doxycycline post-exposure prophylaxis for prevention of sexually transmitted infections among Kenyan women using HIV pre-exposure prophylaxis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,530,733 | August 1, 2019 | July 31, 2025 | BAETEN, JARED | reporter.nih.gov |
| Dispersion and the Biofilm Matrix of Pseudomonas aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,529,490 | March 25, 2021 | February 28, 2027 | SAUER, KARIN | reporter.nih.gov |
| Dissecting the molecular targets to overcome beta-lactam resistance in M. abscessus complex | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,524,458 | June 4, 2025 | May 31, 2030 | KREISWIRTH, BARRY NEAL | reporter.nih.gov |
| Novel Multiple-Stage Active Antimalarials | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,520,964 | June 14, 2019 | August 31, 2030 | KANCHARLA, PAPIREDDY | reporter.nih.gov |
| Broad spectrum inhibitors of paramyxovirus envelope proteins | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,516,477 | August 1, 2023 | July 31, 2027 | MOSCONA, ANNE | reporter.nih.gov |
| Trial to Reduce Antimicrobial Use in Nursing home residents with Alzheimer's disease and other Dementias (TRAIN-AD) | NIH | National Institute on Aging | 2021 to 2025 | $2,515,460 | September 1, 2009 | December 31, 2027 | MITCHELL, SUSAN L | reporter.nih.gov |
| Emerging multidrug resistance mechanisms in Campylobacter | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,513,208 | March 17, 2020 | February 28, 2026 | ZHANG, QIJING | reporter.nih.gov |
| Ultrapotent Inhibitors of Wild-type and Multi-drug Resistant HIV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,507,840 | February 1, 2025 | January 31, 2030 | SARAFIANOS, STEFAN G | reporter.nih.gov |
| Host Immunity in Sepsis-Induced Systemic Infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,506,165 | May 1, 2021 | April 30, 2027 | JEYASEELAN, SAMITHAMBY | reporter.nih.gov |
| Harnessing Antibody Responses to Prevent and Treat Urinary Tract Infections | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,502,664 | November 10, 2021 | October 31, 2026 | KAU, ANDREW LEON | reporter.nih.gov |
| Bioinformatics Tools and Services at NCBI for Combating Antibiotic Resistant Bacteria Research | NIH | National Library of Medicine | 2024 | $2,500,000 | September 28, 2024 | September 27, 2025 | ESSER, HALEY | reporter.nih.gov |
| Bioinformatics Tools and Services for Antimicrobial Resistance Research | NIH | National Library of Medicine | 2025 | $2,500,000 | July 21, 2025 | July 20, 2026 | reporter.nih.gov | |
| Impact of the C. difficile small acid soluble proteins on spore physiology | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,485,925 | August 8, 2022 | July 31, 2027 | SORG, JOE | reporter.nih.gov |
| Targeting the casein kinase 1 (CK1)-like kinase Yck2 in fungal pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,483,708 | March 22, 2022 | February 28, 2027 | COWEN, LEAH ELIZABETH | reporter.nih.gov |
| Predictive Models for Small-Molecule Accumulation in Gram-Negative Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,478,608 | August 10, 2018 | July 31, 2024 | TAN, DEREK S | reporter.nih.gov |
| Long-term impact of universal treatment and dolutegravir on population HIV virologic and incidence outcomes in Africa: The LONGVIEW Study | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,477,786 | April 13, 2021 | March 31, 2026 | GRABOWSKI, MARY KATHRYN | reporter.nih.gov |
| Development of Therapeutic Candidates for Biodefense, Antimicrobial Resistant (AMR) Infections and Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $2,475,623 | May 10, 2024 | November 9, 2025 | FOTOUHI, NADER | reporter.nih.gov |
| Chemical genetics of M. tuberculosis DosRST signaling and persistence | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,472,195 | September 22, 2020 | August 31, 2025 | ABRAMOVITCH, ROBERT B | reporter.nih.gov |
| A unique strategy for reshaping the antibiotics model: chemokine-inspired therapeutics for targeting the host and pathogen to counter infections caused by multidrug-resistant bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,464,828 | September 24, 2020 | August 31, 2025 | HUGHES, MOLLY A | reporter.nih.gov |
| HIV-1 subtype, specific drug resistance in patients failing Dolutegravir-based 1st, 2nd or 3rd line regimens: the International epidemiological Databases to Evaluate AIDS (IeDEA) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,461,630 | September 1, 2021 | August 31, 2025 | EGGER, MATTHIAS | reporter.nih.gov |
| Drug Target Discovery, Validation, and Prioritization for Schistosomiasis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,457,864 | December 20, 2022 | November 30, 2027 | COLLINS, JAMES J | reporter.nih.gov |
| Small-Molecule Penetration and Efflux in Gram-Negative Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,444,282 | March 1, 2024 | January 31, 2029 | TAN, DEREK S | reporter.nih.gov |
| Development of In Vitro Diagnostics for Biodefense, Antimicrobial Resistant Infections, and Emerging Infectious Diseases | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $2,443,961 | August 1, 2024 | July 31, 2026 | KHAKSAR, RAMIN | reporter.nih.gov |
| Environmental regulation of bacterial growth and cell division | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,443,145 | May 1, 2018 | June 30, 2028 | LEVIN, PETRA ANNE | reporter.nih.gov |
| Preventing norovirus and Clostridium difficile gastroenteritis by engineered probiotic yeast Saccharomyces boulardii secreting multi-specific single-domain antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,441,424 | January 22, 2020 | December 31, 2025 | FENG, HANPING | reporter.nih.gov |
| WHO-recommended Periodic Presumptive Treatment versus Doxycycline Post-Exposure Prophylaxis for STI Control among Cisgender Men Who Have Sex with Men in Kenya | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,440,496 | January 19, 2024 | November 30, 2028 | GRAHAM, SUSAN MARIE | reporter.nih.gov |
| Rapid ID and AST Directly from Whole Blood Using Single Molecule Detection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,438,126 | January 30, 2023 | December 31, 2027 | CELEDON, ALFREDO ANDRES | reporter.nih.gov |
| Production of a Gonococcal Vaccine for Countering Antimicrobial Resistance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,429,990 | January 1, 2019 | December 31, 2024 | SCHRYVERS, ANTHONY BERNARD | reporter.nih.gov |
| Epidemiology and determinants of emerging artemisinin-resistant malaria in Ethiopia | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,413,258 | June 9, 2023 | May 31, 2028 | PARR, JONATHAN BOYD | reporter.nih.gov |
| Shared Resource to Investigate Cellular Metabolism | NIH | National Institute of General Medical Sciences | 2021 | $2,412,918 | August 15, 2012 | April 30, 2023 | SMELTZER, MARK S | reporter.nih.gov |
| Let-7b in Extracellular Vesicles Secreted by Bronchial Epithelial Cells Increases the Antibiotic Sensitivity of Pseudomonas | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,409,204 | December 15, 2020 | November 30, 2025 | STANTON, BRUCE A. | reporter.nih.gov |
| BETA LACTAMASE MUTATIONS IN ANTIBIOTIC RESISTANCE | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,404,519 | July 1, 1992 | December 31, 2026 | PALZKILL, TIMOTHY | reporter.nih.gov |
| A Yeast-based Immunotherapy against Clostridioides difficile infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,393,607 | August 1, 2020 | October 31, 2024 | YANG, ZHIYONG | reporter.nih.gov |
| A Preclinical Program for Targeting Mycobacterium tuberculosis KasA | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,385,783 | August 10, 2021 | July 31, 2026 | FREUNDLICH, JOEL STEPHEN | reporter.nih.gov |
| Biosynthesis of Beta Lactam Antibiotics | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,378,474 | February 1, 2016 | July 31, 2026 | TOWNSEND, CRAIG ARTHUR | reporter.nih.gov |
| Fungal dysbiosis regulation of post-influenza bacterial pneumonia | NIH | National Heart, Lung, and Blood Institute | 2021 to 2024 | $2,376,545 | July 16, 2021 | June 30, 2025 | CHEN, PETER | reporter.nih.gov |
| Phage Resistance in Emergent Vibrio cholerae and Phage Prophylaxis of Cholera | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,376,520 | May 15, 2003 | January 31, 2030 | CAMILLI, ANDREW | reporter.nih.gov |
| Biological and structural diversity of bacterial type IV secretion systems | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,372,739 | June 7, 2019 | February 28, 2029 | CHRISTIE, PETER J. | reporter.nih.gov |
| Pathogenic Fiber Formation in Bacteria: Structural Basis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,362,500 | February 1, 2001 | March 31, 2026 | HULTGREN, SCOTT J. | reporter.nih.gov |
| RNA modification and antibiotic resistance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,361,815 | May 1, 2010 | April 30, 2026 | CONN, GRAEME L | reporter.nih.gov |
| Mechanisms Underlying Nutrient-Mediated Sporulation in C. difficile | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,358,945 | June 1, 2021 | May 31, 2027 | MCBRIDE, SHONNA M. | reporter.nih.gov |
| Converting staphylococcal pathogenicity islands from malevolence to benevolence | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,357,606 | January 21, 2019 | March 31, 2025 | NOVICK, RICHARD P. | reporter.nih.gov |
| Investigating Immune-Microbiome interactions during treatment of Clostridioides difficile with fecal microbiome transplantation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,357,199 | February 5, 2021 | January 31, 2027 | ABT, MICHAEL C. | reporter.nih.gov |
| Macrophage nuclear receptors, metabolism and immune effectors during health and M. tuberculosis infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,354,572 | August 7, 2019 | July 31, 2030 | SCHLESINGER, LARRY S. | reporter.nih.gov |
| Boosting efficacy of oral vaccine candidates by enabling spore display of nitrated antigens | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,353,079 | September 8, 2022 | August 31, 2027 | KUNJAPUR, ADITYA MOHAN | reporter.nih.gov |
| Nutritional immunity and microbial competition during Clostridioides difficile infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,352,660 | June 13, 2022 | May 31, 2027 | SKAAR, ERIC P | reporter.nih.gov |
| Elucidating physiology of dormant bacteria to combat antibiotic persistence | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,347,038 | September 1, 2020 | August 31, 2030 | BASAN, MARKUS THOMAS | reporter.nih.gov |
| A prophylactic vaccine to prevent colonization by Pseudomonas aeruginosa | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,345,744 | December 27, 2022 | November 30, 2027 | PICKING, WENDY L. | reporter.nih.gov |
| Genetic Mechanisms of Sporulation Induction in C. difficile | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,343,653 | August 1, 2015 | May 31, 2026 | MCBRIDE, SHONNA M. | reporter.nih.gov |
| Targeting Biotin Metabolism in Mycobacterium Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,339,589 | January 15, 2019 | December 30, 2023 | ALDRICH, COURTNEY C | reporter.nih.gov |
| Cavity and Granuloma Oriented Inflammation and Tissue Pharmacokinetics in Pulmonary Tuberculosis (COOK TB) | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,339,351 | February 9, 2023 | January 31, 2028 | KEMPKER, RUSSELL RYAN | reporter.nih.gov |
| Connecting the Spatiotemporal Organization of Gut Bacterial Communities to the Emergence and Spread of Antibiotic Resistance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,339,120 | May 5, 2021 | October 31, 2026 | WILES, TRAVIS J | reporter.nih.gov |
| Impact of Non - B HIV - 1 Subtype on second line Protease Inhibitor Regimens in Africa (INSPIRE) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,338,871 | April 27, 2020 | December 31, 2026 | NDEMBI, NICAISE | reporter.nih.gov |
| Hijacking Plasmodium ubiquitin-proteasome system to defeat drug resistance | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,334,364 | July 1, 2023 | June 30, 2028 | LIN, GANG | reporter.nih.gov |
| Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South Africa | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,326,177 | March 10, 2022 | February 28, 2027 | O'DONNELL, MAX | reporter.nih.gov |
| Measuring and Predicting Appropriate Antibiotic Use to Combat Resistant Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,321,762 | July 1, 2023 | June 30, 2028 | CHEN, JONATHAN H. | reporter.nih.gov |
| Cardiac microlesion formation during invasive pneumococcal disease | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,308,740 | November 1, 2014 | May 31, 2030 | ORIHUELA, CARLOS J | reporter.nih.gov |
| Follistatin-like 1 Mediated Host Defense in Bacterial Pneumonia | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,305,697 | July 1, 2022 | June 30, 2027 | CAMPFIELD, BRIAN T | reporter.nih.gov |
| VENOUS: A translational study of enterococcal bacteremia | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,305,203 | June 17, 2020 | May 31, 2026 | ARIAS, CESAR AUGUSTO | reporter.nih.gov |
| Role of IL-17 in Protective Vaccine-induced Immune Responses Against Tuberculosis | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,302,219 | December 15, 2010 | July 31, 2026 | KHADER, SHABAANA A. | reporter.nih.gov |
| Molecular mechanisms of inherent drug resistance in non-tuberculous mycobacteria | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,296,095 | September 22, 2023 | July 31, 2028 | RUBIN, ERIC J. | reporter.nih.gov |
| De Novo Synthesis, and Functional and Structural Characterization of Novel Aminoglycoside Analogues to Bypass Resistance Mechanisms and Optimize Selectivity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,295,025 | August 20, 2020 | July 31, 2025 | KIRBY, JAMES E | reporter.nih.gov |
| Surveillance to track and characterize antimalarial resistance trends in Ugandan Plasmodium falciparum parasites (STARTUP) | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,293,828 | December 20, 2022 | November 30, 2025 | CONRAD, MELISSA D | reporter.nih.gov |
| RNA penetrations into bacteria. | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $2,290,185 | August 1, 2022 | June 30, 2026 | ZHANG, JUNJIE | reporter.nih.gov |
| Predictive Guidelines for Penetrance and Discovery of Broad-Spectrum Antibiotics | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,281,750 | February 6, 2018 | January 31, 2024 | HERGENROTHER, PAUL | reporter.nih.gov |
| Rapid phenotypic detection of complex and emergent TB drug-resistance using a next-generation nanoluciferase reporter phage | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,278,505 | April 3, 2023 | March 31, 2028 | O'DONNELL, MAX | reporter.nih.gov |
| Emergence of bedaquiline, pretomanid and linezolid resistance after implementation of new drug-resistant tuberculosis regimens in South Africa | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,277,213 | November 25, 2022 | October 31, 2027 | MATHEMA, BARUN | reporter.nih.gov |
| Evolved Heterogeneity Contributes to Chronic Fungal Lung Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,275,760 | July 19, 2017 | June 30, 2026 | HOGAN, DEBORAH A | reporter.nih.gov |
| Protein Sequencing by Tandem Mass Spectrometry | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $2,271,339 | January 12, 1987 | May 31, 2025 | HUNT, DONALD F | reporter.nih.gov |
| Aneuploidy and Acquired Antifungal Drug Resistance in Candida species | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,271,284 | December 1, 2019 | July 31, 2030 | SELMECKI, ANNA M. | reporter.nih.gov |
| Transition Metal Homeostasis and Reactive Sulfur Species in Bacterial Pathogens | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,271,111 | June 1, 2016 | May 31, 2026 | GIEDROC, DAVID P. | reporter.nih.gov |
| The clinical and molecular epidemiology of colistin-resistant carbapenem-resistant Enterobacteriaceae (CRE) in long-term acute care hospitals (LTACHs) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,270,190 | June 1, 2018 | May 31, 2025 | LAUTENBACH, EBBING | reporter.nih.gov |
| Metabolic Basis of Bacterial Community Function in the Cystic Fibrosis Airway | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,268,565 | June 2, 2021 | May 31, 2026 | O'TOOLE, GEORGE A. | reporter.nih.gov |
| The impact of pyrazinamide on metabolism in Mycobacterium tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,264,154 | March 10, 2021 | February 28, 2026 | BAUGHN, ANTHONY D | reporter.nih.gov |
| Defining P. falciparum resistance to artemisinin-based combination therapies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,262,645 | August 1, 2014 | February 28, 2027 | FIDOCK, DAVID A | reporter.nih.gov |
| Role of Type 2 Immunity in Innate Protection from C. difficile | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,257,824 | February 2, 2016 | January 31, 2027 | PETRI, WILLIAM A | reporter.nih.gov |
| Understanding in vivo antibiotic resistance in diverse Pseudomonas aeruginosa populations | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,254,202 | April 9, 2021 | March 31, 2027 | DIGGLE, STEPHEN PAUL | reporter.nih.gov |
| Culture-free pathogen tracking in hospitalized patients | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,245,086 | April 3, 2020 | March 31, 2025 | BHATT, AMI SIDDHARTH | reporter.nih.gov |
| Synergistic anti-fouling coating and minimal systemic antibiotic injections for combating periprosthetic infections | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2025 | $2,239,544 | August 1, 2022 | May 31, 2027 | SONG, JIE | reporter.nih.gov |
| Chemical biology studies of MmpL3 inhibition and resistance in mycobacteria | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,236,678 | July 13, 2023 | June 30, 2028 | ABRAMOVITCH, ROBERT B | reporter.nih.gov |
| GUARD: A global unbiased antimicrobial discovery platform | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,236,619 | November 7, 2022 | October 31, 2027 | JAYARAMAN, ARUL | reporter.nih.gov |
| Local and global regulation of bacterial growth | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,234,366 | June 1, 2020 | May 31, 2030 | GOLEY, ERIN D | reporter.nih.gov |
| Precise Combination Strategies Targeting Carbapenem-Resistant Klebsiella pneumoniae | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,233,072 | December 5, 2022 | November 30, 2027 | BULMAN, ZACKERY P. | reporter.nih.gov |
| A comprehensive investigation of Pseudomonas quorum sensing regulatory relationships and the consequences on quorum sensing inhibitors in complex communities | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,232,732 | July 1, 2023 | June 30, 2028 | RAHME, LAURENCE G | reporter.nih.gov |
| Rapid, Breath Volatile Metabolite-Based Diagnostic for In Vivo Identification and Antibiotic Resistance Profiling of Bacterial Pathogens in Ventilator-Associated Pneumonia | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $2,232,574 | June 20, 2018 | May 31, 2025 | KOO, SOPHIA | reporter.nih.gov |
| Prevention of intracellular infection in diabetic wounds by commensal Staphylococcus epidermidis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $2,231,277 | May 3, 2023 | April 30, 2027 | TOMIC-CANIC, MARJANA | reporter.nih.gov |
| Mechanism and Inhibition of HIV Reverse Transcriptase | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,228,211 | June 26, 2020 | June 13, 2024 | ANDERSON, KAREN S. | reporter.nih.gov |
| Elevated gene transcription of the cyp51A gene is essential for azole drug resistance in Aspergillus fumigatus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,224,527 | August 6, 2019 | July 31, 2030 | MOYE-ROWLEY, W SCOTT | reporter.nih.gov |
| MEP pathway resistance in Plasmodium falciparum | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,223,785 | December 1, 2012 | March 31, 2028 | ODOM JOHN, AUDREY RAGAN | reporter.nih.gov |
| Automated Sequencing for Culture-free Diagnosis of Drug Resistant TB | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,220,441 | April 17, 2023 | March 31, 2028 | RODWELL, TIMOTHY CHARLES | reporter.nih.gov |
| Diagnostics via Rapid Enrichment, Identification, and Phenotypic Antibiotic Susceptibility Testing of Pathogens from Blood. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,219,076 | May 11, 2018 | April 30, 2024 | WU, BETTY B | reporter.nih.gov |
| Identifying Optimal Treatment Strategies for Tuberculosis Treatment | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,217,092 | January 16, 2019 | December 31, 2024 | SAVIC, RADOJKA | reporter.nih.gov |
| Transcriptional Profiling to Discriminate Bacterial and Non-bacterial Respiratory Illnesses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,207,088 | February 1, 2019 | January 31, 2026 | FALSEY, ANN R | reporter.nih.gov |
| Optimization of efflux avoidance and inhibition for antibiotic development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,205,402 | February 7, 2018 | January 31, 2025 | ZGURSKAYA, HELEN I | reporter.nih.gov |
| Targeting the functions of the gonococcal Type IV pilus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,204,820 | August 1, 2020 | August 31, 2030 | SEIFERT, HANK S. | reporter.nih.gov |
| Multiplexed detection of cell-free M. Tuberculosis DNA and its drug-resistant variants in blood | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,202,681 | August 11, 2023 | July 31, 2028 | HUANG, ZHEN | reporter.nih.gov |
| Finding the way: Sensory adaptation during bacterial mechanotransduction | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,196,569 | June 15, 2023 | May 31, 2028 | ENGEL, JOANNE N. | reporter.nih.gov |
| A novel vaccine against multidrug-resistant gonorrhea | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,179,764 | January 1, 2019 | December 31, 2024 | RAM, SANJAY | reporter.nih.gov |
| Mechanisms and regulation of horizontal gene transfer by natural transformation in Vibrio cholerae | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,178,577 | September 1, 2018 | June 30, 2028 | DALIA, ANKUR | reporter.nih.gov |
| Pathogenesis of Bacterial Keratitis | NIH | National Eye Institute | 2021 to 2025 | $2,177,731 | April 1, 2003 | May 31, 2028 | PEARLMAN, ERIC | reporter.nih.gov |
| RaceCAR-M immunotherapy for cancer and beyond | NIH | National Cancer Institute | 2024 to 2025 | $2,177,000 | September 20, 2024 | August 31, 2029 | MONTELL, DENISE J. | reporter.nih.gov |
| Combating resistant superbugs by understanding the molecular determinants of target site penetration and binding | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,175,842 | August 10, 2018 | July 31, 2024 | BULITTA, JURGEN BERND | reporter.nih.gov |
| An RNA Nanosensor for the Diagnosis of Antibiotic Resistance in M. Tuberculosis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,172,351 | September 1, 2025 | August 31, 2028 | FARHAT, MAHA | reporter.nih.gov |
| Ordered gene knockout libraries for Neisseria gonorrhoeae | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,169,654 | July 1, 2021 | June 30, 2025 | SEIFERT, HANK S. | reporter.nih.gov |
| Injectable Hydrogel Depots for Self-replicating mRNA Vaccine Delivery | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,169,016 | July 12, 2022 | June 30, 2027 | BRYERS, JAMES D. | reporter.nih.gov |
| Point-of-care antimicrobial susceptibility testing based on simultaneous tracking of multi-phenotypic features of single bacterial cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,159,472 | July 25, 2018 | June 30, 2025 | WANG, SHAOPENG | reporter.nih.gov |
| Prevalence, Consequences and Mechanisms of Antibiotic Heteroresistance in Cystic Fibrosis | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $2,158,270 | September 1, 2022 | August 31, 2027 | SINGH, PRADEEP K | reporter.nih.gov |
| Novel bi-specific immunoprophylactics against multi-drug resistant Gram-negativebacterial infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,153,664 | March 22, 2019 | April 30, 2024 | PERLIN, DAVID S | reporter.nih.gov |
| Spore Assembly in Clostridioides difficile | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,151,967 | July 14, 2016 | August 31, 2026 | SHEN, AIMEE | reporter.nih.gov |
| The critical roles of (p)ppGpp in homeostasis and antibiotic tolerance in Gram positive bacteria | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,143,083 | May 1, 2018 | February 29, 2028 | WANG, JUE D. | reporter.nih.gov |
| Optimization of Atypical Antimycobacterial Carbapenem Antibiotics | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,139,287 | July 19, 2023 | June 30, 2028 | BUYNAK, JOHN D | reporter.nih.gov |
| Exploiting Riboswitch Sensors to Reveal Antibiotics Uptake and Retention in Gram Negative Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,138,415 | February 19, 2018 | January 31, 2024 | BREAKER, RONALD R | reporter.nih.gov |
| Long-Acting Prevention Implantable System (LAPIS) for HIV Pre-ExposureProphylaxis (PrEP) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,135,154 | March 6, 2020 | February 28, 2025 | JOHNSON, LEAH | reporter.nih.gov |
| A novel cartridge-based sequencing solution for decentralized M. tuberculosis resistance detection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,133,601 | July 7, 2023 | June 30, 2028 | METCALFE, JOHN ZAPATA | reporter.nih.gov |
| Inhibitors of adaptive efflux mediated resistance in Acinetobacter baumannii | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,131,610 | March 7, 2023 | February 29, 2028 | DUNMAN, PAUL M. | reporter.nih.gov |
| How Regulated Proteolysis Controls Bacterial Virulence | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,130,522 | February 1, 1992 | February 28, 2027 | GROISMAN, EDUARDO | reporter.nih.gov |
| Mechanism(s) of pathogenicity for Candida auris | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,122,714 | February 1, 2020 | January 31, 2027 | NETT, JENIEL E | reporter.nih.gov |
| Vaccine Assembly from Surface Proteins of Staphylococcus aureus | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,121,000 | June 1, 2002 | March 31, 2028 | MISSIAKAS, DOMINIQUE | reporter.nih.gov |
| Macrophage-targeting Nanoplatforms as Immunotherapy against Pulmonary Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,117,352 | July 1, 2017 | November 30, 2028 | SAILOR, MICHAEL J | reporter.nih.gov |
| Orally Bioavailable 4(1H)-Quinolones with Multi-Stage Antimalarial Activity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,114,325 | April 11, 2019 | March 31, 2025 | MANETSCH, ROMAN | reporter.nih.gov |
| Contribution of altered cell envelope metabolism to resistance to cell envelope-targeting antimicrobials in MRSA | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,114,304 | August 15, 2018 | May 31, 2028 | WERTH, BRIAN JAMES | reporter.nih.gov |
| Antibody therapy of MRSA colonization and infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,111,552 | December 13, 2019 | November 30, 2024 | MISSIAKAS, DOMINIQUE M. | reporter.nih.gov |
| Advanced Development of Vaccine Candidates for Antibiotic Resistant Bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,107,829 | September 1, 2020 | February 28, 2025 | RICE, PETER | reporter.nih.gov |
| Aging Microbiome, Immunosenescence, and risk of Multi-drug Resistant Organism Colonization and Infection in the Nursing Home | NIH | National Institute on Aging | 2023 to 2025 | $2,107,076 | February 15, 2023 | November 30, 2027 | HARAN, JOHN PATRICK | reporter.nih.gov |
| Non-canonical functions of Cas9 andthe cell biology of CRISPR-Cas immunity | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,102,958 | August 1, 2021 | May 31, 2026 | MODELL, JOSHUA | reporter.nih.gov |
| Serine/threonine kinase signaling in beta-lactam resistance of Staphylococcus aureus | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,094,960 | August 16, 2023 | July 31, 2027 | CHATTERJEE, SOM | reporter.nih.gov |
| Short and long term outcomes of doxycycline versus TMP-SMX for SSTI treatment | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,085,900 | July 16, 2018 | June 30, 2025 | MILLER, LOREN G. | reporter.nih.gov |
| Diabetes and Antibiotic Treatment Failure | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,080,710 | November 14, 2022 | October 31, 2027 | CONLON, BRIAN PATRICK | reporter.nih.gov |
| Addressing HIV drug resistance research gaps in a cohort of perinatally infected Kenyan children and adolescents | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $2,079,336 | June 27, 2019 | May 31, 2025 | KANTOR, RAMI | reporter.nih.gov |
| Nanostructured degradable bone cement for delivering novel antibiotics | NIH | National Institute of Biomedical Imaging and Bioengineering | 2023 to 2025 | $2,078,876 | September 1, 2023 | August 31, 2027 | SENGUPTA, SHILADITYA | reporter.nih.gov |
| A Pre-, Peri-, and Post-natal Approach to Understanding the Risk and Mechanisms for Obesity | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $2,076,908 | May 1, 2023 | February 29, 2028 | COMSTOCK, SARAH S. | reporter.nih.gov |
| Understanding pathogen and host determinants of the natural history of N. gonorrhoeae infection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,068,068 | June 23, 2023 | May 31, 2028 | DUNCAN, JOSEPH A | reporter.nih.gov |
| Investigating nanobodies to target multidrug resistant bacterial pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,059,761 | August 1, 2020 | July 31, 2025 | DAVIES, BRYAN WILLIAM | reporter.nih.gov |
| Early detection and inference for emerging infectious agents in data-sparse settings | NIH | National Institute of General Medical Sciences | 2025 | $2,056,250 | September 1, 2025 | August 31, 2029 | PEI, SEN | reporter.nih.gov |
| DEVELOPMENT OF A NOVEL CLASS OF ANTIBIOTICS AGAINST VIBRIO CHOLERAE NA+-NQR | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,055,320 | December 13, 2021 | November 30, 2026 | JUAREZ, OSCAR | reporter.nih.gov |
| Mapping epistatic interactions in molecular evolution of antibiotic resistance | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $2,044,244 | April 9, 2018 | April 30, 2027 | TOPRAK, ERDAL | reporter.nih.gov |
| Redefining Tuberculosis Meningitis with Metagenomics and Host Transciptomics | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,043,168 | March 11, 2019 | February 28, 2025 | WILSON, MICHAEL R | reporter.nih.gov |
| Regulation of C. difficile colitis by host genetic and immune factors | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,039,928 | September 17, 2021 | August 31, 2026 | MADAN, RAJAT | reporter.nih.gov |
| Development of a mechanistically novel Gram-negative antibiotic targeting MsbA-mediated Lipopolysaccharide Biogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,038,369 | November 4, 2022 | October 31, 2027 | ROEMER, TERRY | reporter.nih.gov |
| Synergistic killing of bacterial pathogens by histones | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,035,091 | July 12, 2022 | June 30, 2027 | SIRYAPORN, ALBERT | reporter.nih.gov |
| Immunization against filamentous bacteriophages to prevent bacterial infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,033,928 | June 8, 2018 | May 31, 2025 | EVANS, JAY T. | reporter.nih.gov |
| An automated culture-free system for the identification of bloodstream infections direct from blood | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,027,841 | July 8, 2024 | June 30, 2027 | SINGER, ALON | reporter.nih.gov |
| Fecal Microbiota Transplant for C. difficile Infection in Solid Organ Transplant Recipients | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,027,511 | September 15, 2018 | August 31, 2023 | SAFDAR, NASIA | reporter.nih.gov |
| Molecular Insights into the Uropathogenesis of MDR Acinetobacter baumannii | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,021,352 | February 6, 2019 | January 31, 2025 | FELDMAN, MARIO | reporter.nih.gov |
| Novel Electrochemical Bandage for Treatment of Wound Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,019,831 | May 1, 2011 | May 31, 2030 | PATEL, ROBIN | reporter.nih.gov |
| Preclinical development of a biological antiviral for universal influenza treatment and prophylaxis using a novel nucleic acid delivery platform | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,019,810 | August 20, 2018 | March 31, 2024 | LINKE, LYNDSEY | reporter.nih.gov |
| Preclinical optimization of a parasiticidal drug for cryptosporidiosis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,017,526 | March 1, 2019 | February 28, 2025 | HUSTON, CHRISTOPHER D | reporter.nih.gov |
| The Function of Antimalarial Drug Resistance Proteins | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,016,655 | June 15, 2003 | October 31, 2026 | ROEPE, PAUL D. | reporter.nih.gov |
| Mechanisms of HIV fitness and drug resistance inferred from high-resolution molecular dynamics and sequence co-variation models | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,014,743 | August 1, 2023 | July 31, 2028 | LEVY, RONALD | reporter.nih.gov |
| Uncovering aryl polyene biology to identify new drug targets in Gram-negative bacterial pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,012,500 | April 1, 2021 | March 31, 2027 | CLAESEN, JAN | reporter.nih.gov |
| Gonococci: Genetics of Resistance to PMN Proteins | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,011,486 | April 1, 1984 | August 31, 2026 | SHAFER, WILLIAM MAURICE | reporter.nih.gov |
| Mechanistic Studies of Gyrase/Topoisomerase IV-Targeted Antibacterials | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,006,826 | March 23, 2023 | February 28, 2027 | OSHEROFF, NEIL | reporter.nih.gov |
| Radical SAM-dependent methylation in antibiotic resistance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,005,023 | September 14, 2018 | April 30, 2028 | FUJIMORI, DANICA GALONIC | reporter.nih.gov |
| Biogenesis of cyclic and phospholipid-linked enterobacterial common antigen | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,004,579 | June 9, 2021 | July 31, 2026 | MITCHELL, ANGELA MARIE | reporter.nih.gov |
| Emerging antibiotic resistance in Gram-negative pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $2,001,153 | February 1, 2019 | January 31, 2025 | YU, EDWARD W | reporter.nih.gov |
| Rapid discovery of thousands of intact biosynthetic gene pathways for bioactive natural product compounds from un-sequenced filamentous fungi using a novel FAC-NGS tool | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,000,000 | January 15, 2019 | August 31, 2023 | WU, CHENGCANG CHARLES | reporter.nih.gov |
| A Culture-Free Platform for Rapid Fungal Pathogen Identification | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,000,000 | August 1, 2014 | March 31, 2024 | SINGER, ALON | reporter.nih.gov |
| A new class of broad-spectrum antibacterials for treating MDR infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,000,000 | May 1, 2020 | April 30, 2023 | TESTA, CHARLES | reporter.nih.gov |
| Immunotherapy of MRSA Osteomyelitis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,000,000 | May 12, 2021 | April 30, 2023 | AMAN, M JAVAD | reporter.nih.gov |
| Development of WecA-targeting immune potentiators to treat carbapenem-resistant Enterobacteriaceae (CRE) infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $2,000,000 | August 1, 2019 | July 31, 2024 | ROEMER, TERRY | reporter.nih.gov |
| Novel Cyclic Boronate Cell Wall Inhibitors Targeting Carbapenem-Resistant Acinetobacter baumannii | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,000,000 | April 1, 2024 | March 31, 2027 | UEHARA, TSUYOSHI | reporter.nih.gov |
| New oral antibiotics focused on treating MDR Gram-negative infections | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $2,000,000 | July 9, 2024 | June 30, 2027 | TESTA, CHARLES | reporter.nih.gov |
| A method for accurate and sensitive detection of HIV drug-resistant minority variants | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2023 | $1,999,999 | March 15, 2016 | June 30, 2025 | WANG, GARY P. | reporter.nih.gov |
| A new class of antibiotic to address Antimicrobial Resistance | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,999,995 | May 1, 2024 | April 30, 2027 | TESTA, CHARLES | reporter.nih.gov |
| Baseline pRescription According to Direct from Sputum Sequencing and TArgeted drug Concentration Strategy (BRASS TACS) | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,998,000 | April 7, 2023 | March 31, 2028 | TORNHEIM, JEFFREY | reporter.nih.gov |
| Informatics Approaches to Understand and Reduce Inappropriate Antibiotic Prescribing by Dentists | NIH | National Institute of Dental & Craniofacial Research | 2023 to 2025 | $1,997,505 | August 1, 2023 | July 31, 2028 | WALJI, MUHAMMAD | reporter.nih.gov |
| 2/2: AZithromycin Therapy in Preschoolers with a Severe Wheezing Episode Diagnosed at the Emergency Department (AZ-SWED) | NIH | National Heart, Lung, and Blood Institute | 2022 to 2025 | $1,997,251 | September 15, 2020 | November 15, 2026 | CASPER, THERON C | reporter.nih.gov |
| Resorbable Antimicrobial Envelope to Prevent Infection of Implanted Cardiac Devices | NIH | National Heart, Lung, and Blood Institute | 2022 to 2023 | $1,995,642 | September 1, 2018 | June 14, 2025 | BRUNNER, GLENN | reporter.nih.gov |
| Coordinate Regulation of Salmonella Virulence and Antimicrobial Resistance by MarR Transcription Factors | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,994,457 | June 1, 2020 | May 31, 2026 | FANG, FERRIC C | reporter.nih.gov |
| Teixobactin Development for Anthrax | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,989,172 | June 15, 2020 | May 31, 2024 | HUGHES, DALLAS | reporter.nih.gov |
| ELD607 Orai1 Antagonist Increases Bacterial Clearance from the Lung | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,988,078 | June 22, 2020 | June 30, 2025 | TARRAN, ROBERT | reporter.nih.gov |
| Biofilm disrupting antibody to treat respiratory and musculoskeletal infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,980,222 | September 1, 2020 | August 31, 2023 | KAUVAR, LAWRENCE MICHAEL | reporter.nih.gov |
| Adaptive alterations of lipids in mitis group streptococci | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,979,502 | September 23, 2020 | August 31, 2025 | PALMER, KELLI LEA | reporter.nih.gov |
| Transport across two membranes by AcrAB-TolC | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,975,491 | March 1, 2003 | March 31, 2026 | ZGURSKAYA, HELEN I | reporter.nih.gov |
| Rapid Low Cost Phenotypic Antibiotic Susceptibility Testing | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,975,326 | February 7, 2017 | March 31, 2023 | RHODES, PAUL | reporter.nih.gov |
| Cyclic Orynotides for Systemic MDR Candidiasis | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,974,899 | May 7, 2019 | April 30, 2024 | TRAN, DAT QUANG | reporter.nih.gov |
| Protection Against Nosocomial Infections After Severe Burn Injury Through Trained Immunity | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $1,970,710 | May 1, 2021 | April 30, 2025 | BOHANNON, JULIA K. | reporter.nih.gov |
| Multivalent Toxoid Vaccine for recurrent Staphylococccus aureus disease | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,966,087 | August 1, 2014 | February 28, 2027 | AMAN, M JAVAD | reporter.nih.gov |
| Listeria monocytogenes physiology and host pathogen interactions | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,964,244 | February 1, 2015 | January 31, 2026 | WOODWARD, JOSHUA | reporter.nih.gov |
| Bone targeted delivery of an antimicrobial drug for osteomyelitis therapy | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,964,220 | July 1, 2016 | December 31, 2023 | EBETINO, FRANK H. | reporter.nih.gov |
| Pathobiology of MRSA-induced Endothelial Permeability and Acute Lung Injury | NIH | National Heart, Lung, and Blood Institute | 2023 to 2025 | $1,963,994 | December 20, 2022 | November 30, 2026 | DUDEK, STEVEN M | reporter.nih.gov |
| Multiplexed Assay for Point-of-Care UTI Diagnosis (ID/AMR) | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,961,669 | March 1, 2024 | February 28, 2027 | BURKLUND, ALISON | reporter.nih.gov |
| Immunotherapeutic approach for the prevention of secondary infection with drug-resistant TB | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,956,687 | June 13, 2024 | April 30, 2029 | COLER, RHEA N | reporter.nih.gov |
| Interplay of M. tuberculosis trehalose metabolism and its pathogenesis and drug resistance | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,953,308 | March 16, 2023 | February 28, 2027 | EOH, HYUNGJIN | reporter.nih.gov |
| Global Circuitry that Controls Acinetobacter Resistance and Virulence | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,948,580 | July 26, 2021 | June 30, 2027 | GEISINGER, EDWARD | reporter.nih.gov |
| Impact of Foreign Bodies on Infection Susceptibility, Disease and Mucosal Remodeling of the Urinary Tract | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $1,947,026 | January 1, 1997 | December 31, 2027 | HULTGREN, SCOTT J. | reporter.nih.gov |
| Mechanisms of allostery and molecular recognition in efflux pumps | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,946,465 | July 15, 2014 | August 3, 2025 | TRAASETH, NATHANIEL J. | reporter.nih.gov |
| Innovating anti-tuberculosis drug susceptibility testing with a novel and rapid non-culture based phenotypic test using MPT64 biomarker | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,942,637 | April 4, 2023 | March 31, 2028 | KATO-MAEDA, MIDORI | reporter.nih.gov |
| Molecular regulation of stress sensing and processing in gram-positive and gram-negative bacterial models. | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $1,933,573 | September 15, 2020 | August 31, 2030 | CABEEN, MATTHEW T | reporter.nih.gov |
| Improved Therapeutics and Diagnostics for Pneumocystis Pneumonia | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,932,841 | February 1, 2016 | October 31, 2026 | KOLLS, JAY K | reporter.nih.gov |
| Advancing innovative therapies against pandrug-resistant Gram-negative superbugs | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,931,905 | July 1, 2019 | June 30, 2025 | ZHOU, QI | reporter.nih.gov |
| General and High-Throughput Small Molecule Screens and Selections for Metabolic Engineering | NIH | National Institute of General Medical Sciences | 2021 to 2023 | $1,931,138 | April 1, 2020 | February 28, 2025 | CORNISH, VIRGINIA W | reporter.nih.gov |
| Tethered aza-Wacker Technology for Complex Antibiotic Assembly | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $1,930,783 | September 1, 2021 | July 31, 2027 | SATHYAMOORTHI, SHYAM | reporter.nih.gov |
| Novel DNA encoded monoclonal antibodies (DMAbs) for control of Antimicrobial Resistant (AMR) Pseudomonas aeruginosa infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2022 | $1,929,790 | September 1, 2019 | August 31, 2025 | WEINER, DAVID B. | reporter.nih.gov |
| Identification of new inhibitors of essential functions in M. tuberculosis by high-throughput metabolic profiling | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,927,436 | November 18, 2022 | October 31, 2027 | BERNEY, MICHAEL | reporter.nih.gov |
| Parallel phenotyping to dissect genetic determinants of bacterial strain diversity | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,920,876 | August 9, 2022 | July 31, 2027 | CAREY, ALLISON | reporter.nih.gov |
| Discovery and Characterization of Natural Product Systems | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $1,917,817 | June 1, 2016 | May 31, 2026 | SHERMAN, DAVID H | reporter.nih.gov |
| Engineered Polymer Nanoemulsions for Treatment of Wound Biofilm Infections | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,913,593 | July 24, 2018 | June 30, 2027 | ROTELLO, VINCENT M. | reporter.nih.gov |
| Novel, Non-Toxic Ocular Antiseptic For Intravitreal Injection Therapy | NIH | National Eye Institute | 2021 to 2022 | $1,913,270 | April 1, 2020 | March 31, 2024 | SMITH, STEPHEN J | reporter.nih.gov |
| Oral Immunotherapy with IgA to Treat C. difficile Infection | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2023 | $1,912,856 | April 14, 2022 | March 31, 2025 | SIMON, MICHAEL R | reporter.nih.gov |
| Accelerating phage evolution and tools via synthetic biology and machine learning | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2024 | $1,910,830 | September 16, 2019 | May 31, 2025 | NUGEN, SAM R | reporter.nih.gov |
| Novel mechanisms contributing to failure of dolutegravir-containing cART in clinical practice | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,910,224 | August 20, 2019 | July 31, 2024 | VAN DE VIJVER, DAVID | reporter.nih.gov |
| Role of ribosome modulating proteins in conferring Mycobacterium abscessus antibiotic resistance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,909,990 | September 21, 2020 | August 31, 2025 | GHOSH, PALLAVI | reporter.nih.gov |
| Enhancing Innate Anti-Viral Resistance Through A Community-Based Intervention | NIH | National Institute on Aging | 2022 to 2024 | $1,909,300 | March 15, 2022 | February 29, 2028 | COLE, STEVE W | reporter.nih.gov |
| Nanohybrid Composites Minimize Antibiotic Resistant Infections | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,906,830 | August 20, 2024 | July 31, 2029 | LI, BINGYUN | reporter.nih.gov |
| Structural determinants of activity and mechanism of cationic peptide antibiotic activity against colistin-resistant bacteria | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,906,715 | June 1, 2023 | May 31, 2028 | DESLOUCHES, BERTHONY | reporter.nih.gov |
| Role and regulation of peptidoglycan synthases in enterococcal antimicrobial resistance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,906,568 | March 10, 2020 | February 28, 2026 | KRISTICH, CHRISTOPHER J | reporter.nih.gov |
| ATP Binding Cassette (ABC) Transporters in Fungal Drug Tolerance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,902,785 | July 1, 2021 | June 30, 2027 | TOMASIAK, THOMAS MICHAEL | reporter.nih.gov |
| Eradicating persistent M. tuberculosis by synthetic lethality of terminal respiratory oxidases | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2023 | $1,893,366 | November 13, 2018 | October 31, 2025 | BERNEY, MICHAEL | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| University of California Los Angeles | Los Angeles, CA | 7 | $479.9 million | 0 | $0 |
| Duke University | Durham, NC | 18 | $99.8 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 50 | $74.9 million | 0 | $0 |
| Emory University | Atlanta, GA | 46 | $67.7 million | 0 | $0 |
| American Type Culture Collection | Manassas, VA | 2 | $63.1 million | 0 | $0 |
| Univ of North Carolina Chapel Hill | Chapel Hill, NC | 43 | $61 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 53 | $57.4 million | 0 | $0 |
| University of Washington | Seattle, WA | 34 | $52.8 million | 0 | $0 |
| Washington University | Saint Louis, MO | 42 | $51.3 million | 0 | $0 |
| Venatorx Pharmaceuticals, Inc. | Malvern, PA | 7 | $51.1 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 42 | $49.6 million | 0 | $0 |
| Technical Resources International, Inc. | Bethesda, MD | 1 | $48 million | 0 | $0 |
| Revagenix, Inc. | San Mateo, CA | 2 | $37.2 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 25 | $34.8 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 43 | $34.3 million | 0 | $0 |
| Stanford University | Stanford, CA | 21 | $32.7 million | 0 | $0 |
| Crestone, Inc. | Boulder, CO | 3 | $32.5 million | 0 | $0 |
| University of Maryland Baltimore | Baltimore, MD | 21 | $31.8 million | 0 | $0 |
| New York University School of Medicine | New York, NY | 12 | $30.7 million | 0 | $0 |
| Sri International | Menlo Park, CA | 1 | $27.9 million | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 12 | $26.5 million | 0 | $0 |
| University of Virginia | Charlottesville, VA | 24 | $26.5 million | 0 | $0 |
| Univ of Massachusetts Med SCH Worcester | Worcester, MA | 17 | $25.6 million | 0 | $0 |
| Vanderbilt University Medical Center | Nashville, TN | 22 | $25.3 million | 0 | $0 |
| Ut Southwestern Medical Center | Dallas, TX | 16 | $24.5 million | 0 | $0 |
| Research Triangle Institute | Research Triangle Park, NC | 3 | $24.5 million | 0 | $0 |
| University of Rochester | Rochester, NY | 10 | $23.8 million | 0 | $0 |
| Yale University | New Haven, CT | 21 | $22 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 13 | $21.9 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 19 | $21.8 million | 0 | $0 |
| University of Wisconsin-Madison | Madison, WI | 24 | $21 million | 0 | $0 |
| University of Notre Dame | Notre Dame, IN | 13 | $20.9 million | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 14 | $20 million | 0 | $0 |
| Harvard University D/b/a Harvard School of Public Health | Boston, MA | 15 | $19.9 million | 0 | $0 |
| Rutgers Biomedical and Health Sciences | Newark, NJ | 12 | $19.4 million | 0 | $0 |
| Hackensack University Medical Center | Hackensack, NJ | 12 | $19.3 million | 0 | $0 |
| Albert Einstein College of Medicine | Bronx, NY | 10 | $18.7 million | 0 | $0 |
| ST. Jude Children's Research Hospital | Memphis, TN | 14 | $18.4 million | 0 | $0 |
| Rockefeller University | New York, NY | 6 | $17.7 million | 0 | $0 |
| Cornell University | Ithaca, NY | 18 | $17.3 million | 0 | $0 |
| University of Southern California | Los Angeles, CA | 11 | $17.3 million | 0 | $0 |
| University of South Florida | Tampa, FL | 14 | $17.2 million | 0 | $0 |
| Harvard Medical School | Boston, MA | 20 | $16.8 million | 0 | $0 |
| University of California-Irvine | Irvine, CA | 13 | $16.4 million | 0 | $0 |
| University of Utah | Salt Lake City, UT | 11 | $16 million | 0 | $0 |
| University of Illinois at Chicago | Chicago, IL | 16 | $15.8 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 19 | $15.7 million | 0 | $0 |
| Harvard University | Cambridge, MA | 8 | $15.4 million | 0 | $0 |
| University of Georgia Research Foundation Inc | Athens, GA | 17 | $15.3 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 20 | $15.1 million | 0 | $0 |
| Northeastern University | Boston, MA | 7 | $14.9 million | 0 | $0 |
| Thomas Jefferson University | Philadelphia, PA | 8 | $14.8 million | 0 | $0 |
| Tufts University Boston | Boston, MA | 17 | $14.5 million | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 15 | $14.5 million | 0 | $0 |
| University of Iowa | Iowa City, IA | 18 | $14.4 million | 0 | $0 |
| University of Maryland, College Park | College Park, MD | 9 | $14.3 million | 0 | $0 |
| University of Texas HLTH Sci CTR Houston | Houston, TX | 17 | $14.1 million | 0 | $0 |
| Seattle Children's Hospital | Seattle, WA | 9 | $14.1 million | 0 | $0 |
| Purdue University | West Lafayette, IN | 9 | $14 million | 0 | $0 |
| Dartmouth College | Hanover, NH | 8 | $13.6 million | 0 | $0 |
| SUNY at Buffalo | Amherst, NY | 11 | $13.4 million | 0 | $0 |
| Baylor College of Medicine | Houston, TX | 12 | $13.4 million | 0 | $0 |
| University of Texas at Austin | Austin, TX | 10 | $13.3 million | 0 | $0 |
| University of Chicago | Chicago, IL | 9 | $13.2 million | 0 | $0 |
| Tulane University of Louisiana | New Orleans, LA | 6 | $13.2 million | 0 | $0 |
| Helixbind, Inc. | Boxborough, MA | 5 | $13.1 million | 0 | $0 |
| Novobiotic Pharmaceuticals, LLC | Cambridge, MA | 6 | $13 million | 0 | $0 |
| University of Illinois at Urbana-Champaign | Urbana, IL | 10 | $12.9 million | 0 | $0 |
| Georgia State University | Atlanta, GA | 8 | $12.9 million | 0 | $0 |
| SUNY at Stony Brook | Stony Brook, NY | 9 | $12.9 million | 0 | $0 |
| Methodist Hospital Research Institute | Houston, TX | 13 | $12.7 million | 0 | $0 |
| Ohio State University | Columbus, OH | 16 | $12.1 million | 0 | $0 |
| Microbiotix, INC | Worcester, MA | 9 | $11.9 million | 0 | $0 |
| Michigan State University | East Lansing, MI | 12 | $11.5 million | 0 | $0 |
| University of Arizona | Tucson, AZ | 5 | $11.5 million | 0 | $0 |
| Case Western Reserve University | Cleveland, OH | 11 | $11.4 million | 0 | $0 |
| University of Florida | Gainesville, FL | 13 | $11.3 million | 0 | $0 |
| Eveliqure Biotechnologies, GMBH | Veinna | 1 | $11.3 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 12 | $11.1 million | 0 | $0 |
| Forge Therapeutics, Inc. | San Diego, CA | 1 | $11 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 11 | $10.9 million | 0 | $0 |
| Nubad, LLC | Greer, SC | 7 | $10.8 million | 0 | $0 |
| Texas Biomedical Research Institute | San Antonio, TX | 6 | $10.6 million | 0 | $0 |
| Indiana University | Bloomington, IN | 7 | $10.6 million | 0 | $0 |
| Spero Therapeutics, Inc. | Cambridge, MA | 1 | $10.5 million | 0 | $0 |
| Children's Hosp of Philadelphia | Philadelphia, PA | 9 | $10 million | 0 | $0 |
| Curza INC | Salt Lake City, UT | 5 | $9.9 million | 0 | $0 |
| Prokaryotics, Inc. | Union, NJ | 9 | $9.9 million | 0 | $0 |
| Oregon Health & Science University | Portland, OR | 10 | $9.8 million | 0 | $0 |
| New York University | New York, NY | 6 | $9.8 million | 0 | $0 |
| Gheskio Center | Port-Au-Prince | 1 | $9.7 million | 0 | $0 |
| Dynport Vaccine Company, LLC | Frederick, MD | 2 | $9.6 million | 0 | $0 |
| Arietis | Boston, MA | 3 | $9.6 million | 0 | $0 |
| The University of Central Florida Board of Trustees | Orlando, FL | 8 | $9.3 million | 0 | $0 |
| Stellenbosch University | Stellenbosch | 6 | $9.1 million | 0 | $0 |
| Trustees of Boston University | Boston, MA | 4 | $9 million | 0 | $0 |
| Louisiana State University | Baton Rouge, LA | 7 | $9 million | 0 | $0 |
| University of California-Berkeley | Berkeley, CA | 8 | $8.9 million | 0 | $0 |
| Lundquist Institute for Biomedical Innovation at Harbor-Ucla Medical Center | Torrance, CA | 6 | $8.8 million | 0 | $0 |
| Georgia Tech Research Corporation | Atlanta, GA | 11 | $8.5 million | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 929 | $610,094,938 | 0 | $0 |
| 2024 | 1,022 | $631,970,363 | 0 | $0 |
| 2023 | 1,004 | $676,526,188 | 0 | $0 |
| 2022 | 998 | $730,896,928 | 0 | $0 |
| 2021 | 1,021 | $697,253,904 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| Change of Recipient Organization (Type 7 Parent Clinical Trial Optional) | PA-24-254 | NIH | July 12, 2027 | Not listed | Notice number printed on 9 awards here | |
| NIH Pathway to Independence Award (Parent K99/R00 Independent Clinical Trial Not Allowed) | PA-24-194 | NIH | May 7, 2027 | Not listed | Notice number printed on 6 awards here | |
| Mentored Clinical Scientist Research Career Development Award (Parent K08 Independent Clinical Trial Not Allowed) | PA-24-182 | NIH | May 8, 2027 | Not listed | Notice number printed on 4 awards here | |
| Midcareer Investigator Award in Patient-Oriented Research (Parent K24 Independent Clinical Trial Not Allowed) | PA-24-188 | NIH | May 7, 2027 | Not listed | Notice number printed on 3 awards here | |
| Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed) | PA-24-185 | NIH | May 7, 2027 | Not listed | Notice number printed on 3 awards here | |
| Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed) | PAR-24-296 | NIH | December 3, 2026 | Not listed | Notice number printed on 1 award here | |
| Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required) | RFA-AI-27-002 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 1,580 awards here |
| Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required) | RFA-AI-27-005 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 1,580 awards here |
| Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional) | PAR-25-370 | NIH | 93.855 | November 16, 2026 | $50,000 | Same assistance listing 93.855 as 1,580 awards here |
| Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | PAR-25-369 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 1,580 awards here |
| Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) | PAR-25-371 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 1,580 awards here |
| Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) | PAR-25-379 | NIH | 93.855 | January 7, 2027 | Not listed | Same assistance listing 93.855 as 1,580 awards here |
| HIV/AIDS Clinical Trials Network Leadership and Operations Centers | RFA-AI-28-001 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 1,580 awards here |
| HIV/AIDS Clinical Trials Network Laboratory Centers | RFA-AI-28-002 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 1,580 awards here |
| HIV/AIDS Clinical Trials Network Statistical and Data Management Centers | RFA-AI-28-003 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 1,580 awards here |
| HIV/AIDS Clinical Trials Network Clinical Trials Units | RFA-AI-28-004 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 1,580 awards here |
| Precision and Systems Biology to Uncover the Link Between Chronic and Infectious Diseases | RFA-AI-28-014 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 1,580 awards here |
| Immune Tolerance Network (UM1 Clinical Trial Required) | RFA-AI-28-005 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 1,580 awards here |
| Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed) | RFA-AI-28-012 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 1,580 awards here |
| Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) | RFA-AI-28-024 | NIH | 93.855 | February 11, 2027 | Not listed | Same assistance listing 93.855 as 1,580 awards here |
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.